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ABSTRACT 
Onyinyechukwu Okolie: Intra-cavity Stem Cells Target Post-Surgical Brain Tumor Progression 
in Novel Resection and Recurrence Mouse Models 
(Under the direction of Shawn Hingtgen) 
 
Surgical resection is a universal component of therapy against aggressive brain tumors. 
These cancers include glioblastoma (GBM) and medulloblastoma (MB), which are prevalent in 
older adults and children, respectively. Due to limited pre-clinical models, little is known about 
the post-operative microenvironment and how it impacts efficacy of local therapies. Cytotoxic 
stem cells (SCs) have emerged as a promising approach to target these aggressive post-surgical 
brain cancers, due in large part to their inherent tumor-homing properties. Our goal is to develop 
scaffold technology to improve stem cell therapy for post-surgical brain tumors. Though, in order 
to develop this new stem cell technology, there needs to be animal models in which to test this 
therapy. Thus, in chapter two, we created the first GBM resection and recurrence model in an 
immune-competent mice. This model allowed us to observe surgery-mediated events that may 
potentiate tumor aggressiveness and efficacy of local stem therapies. In chapter three, we tested 
different scaffold materials that were loaded with cytotoxic stem cells in our GBM resection 
models. We found that therapeutic stem cells loaded on these materials inhibited post-surgical 
tumor recurrence. Lastly, in chapter four, we utilize stem cell-scaffold technology in an entirely 
new model of surgical resection, new disease, and new stem cells for pediatric patients. Using 
therapeutic stem cells derived from pediatric human patients, this therapy delayed post-surgical 
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tumor recurrence and extended median survival in tumor-bearing mice. These studies demonstrate 
a novel model of GBM and MB resection and recurrence that provided a platform to develop and 
advance stem cell technologies in a post-surgical cavity. In addition, the results also suggest that 
intra-cavity SC therapy is a viable new option to effectively control post-operative tumor growth 
in GBM and MB patients. 
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PREFACE 
 
During my years as an undergraduate student I was able to grow a curiosity in a broad 
range of science. One of those paths led me to a role in working with cancer therapy. Once I 
discovered the nuances and different avenues I could pursue I knew I had found my niche. One of 
the many reasons why I enjoy working with such an intense form of science had to do with the 
research I was exposed to upon entering graduate school. Hearing about how aggressive cancer 
can be sparked an interest that I knew I needed to satisfy. So many people are affected by cancer 
and personally my wife has had a relative pass away because of this debilitating disease. I knew if 
there was a way to change how we think about cancer, treat cancer and approach the disease itself 
that I wanted to be a part of that discovery.  
Throughout my years as a researcher I have learned a great deal that will change me for the 
rest of my life. The way I think about people and the way I think about families having to deal 
with cancer is a mindset I would never want to trade for anything else. My time in the laboratory, 
with peers, during experiments, and even in classes has trained, taught and molded me into the 
individual I am today.  
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Why of all cancers did I pursue brain cancer? Because there is nothing else I would rather 
do. It easily has one of the most life changing effects on human life. Why would not I want to fix 
something that has such a huge negative impact on our future? I look forward to the time when I 
can see the results of the late nights, early projects, and timeless conversations turn into something 
so dramatic and life-changing. And I am proud and thrilled to be a part of the change I know is 
coming to better the lives of many. 
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CHAPTER 1: INTRODUCTION 
 
Glioblastoma (GBM) and Medulloblastoma (MB) are two of the most common and 
aggressive primary brain malignancies.1,2 Though both tumors diffusely invade normal tissue, MB 
is able to extensively disseminate within the cerebral spinal fluid (CSF) and subarachnoid space 
to form micro-metastases.3,4 The standard of care for MB involves surgical resection, multi-drug 
chemotherapy, and irradiation of the cerebrospinal axis. Despite a 60% 5-year survival, nearly all 
MB patients experience long-term developmental and cognitive deficits.5 In contrast, GBM is 
characterized by its more rapid growth kinetics.6,7 The standard treatment regimen for GBM 
involves surgical resection followed by chemotherapy and radiation. Despite technological 
advances in the standard of care, GBM patients have a median survival of approximately 15 
months.8 Thus, effective alternative therapies are needed to battle these lethal intracranial diseases.  
The majority of cancer therapies are unable to effectively cross the blood brain barrier 
(BBB) and have unfavorable pharmacokinetics, therefore preventing adequate drug accumulation 
at the tumor site.9,10 One strategy to overcome these challenges is the utilization of locally 
administered stem cells (SCs) as drug delivery vehicles for biologics. SCs engineered with 
cytotoxic agents display intrinsic tumor-homing properties allowing for selective targeting of 
cancer cells while minimizing off-target toxicity. Herein, we discuss the sources, tumor-tropism, 
and the therapeutic utilization of SCs for cancer treatment in pre-clinical and clinical settings. 
 
2 
Stem cell sources 
Three main categories of SCs have emerged over the past 15 years of research: adult, 
embryonic, and reprogrammed.  
Adult SCs include mesenchymal (MSC) and neural stem cells (NSC) and have been 
extensively explored for cancer therapeutics. MSCs have been isolated from numerous sources 
such as bone-marrow, adipose tissue, and umbilical cord blood and tissue.11 These multi-potent 
cells are responsible for cellular homeostasis and can differentiate into fat, bone, cartilage, and 
muscle cells. NSCs are primarily located within the subventricular zone and in the dentate gyrus 
and are capable of self-renewal and differentiation into both glial and neuronal lineages.12 These 
adult cells lack many of the safety and ethical concerns of induced pluripotent reprogramming and 
embryonic SCs for cancer treatment. There are significant advantages to both types of adult SCs. 
MSCs are readily available compared to other SCs and NSC are the only endogenous SCs in the 
brain.13-15 
Embryonic stem cells (ESCs) refer to pluripotent cell populations located within the 
embryo that can give rise to any of the three germ layers.16 However, due to ethical issues, these 
cells are less frequently used in biomedical research. Reprogrammed stems cells include both 
transcriptionally induced pluripotent and induced cells. Induced pluripotent stem cells (iPSCs) are 
generated from somatic cells and can regenerate the three germ layers. These cells are 
reprogrammed by introducing a cocktail of transcription factors (c-Myc, Kf4, Oct3/4 and Sox2) to 
somatic cells.17 iPSCs can further differentiate into MSCs or NSCs. Induced cells are generated by 
direct conversion from somatic cells without passing through a pluripotent stem cell 
intermediate.18-20 Safety concerns have limited the therapeutic use of this category of stem cell.21 
Induced neural stem cells (iNSCs) overcome the limitations plaguing iPSC for cancer therapy. 
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These cells are directly reprogrammed to NSCs without passing through the unsafe pluripotent 
stage.18,19,22-24  
Stem cell sources also play a role in safety and in other areas we will further discuss later 
such as SC persistence and therapeutic efficacy. In brief, the study by Gao et al. injected ESCs, 
iPSC, adult (NSC, MSC), and iNSC into syngeneic mouse brains.25 They discovered that ESC and 
iPSC cells formed tumors while iNSCs, NSCs, and MSCs were not tumorigenic and did not show 
signs of immune rejection. Those three cell types have been used extensively and known to survive 
long-term in mouse brains.26-29 Though this will be discussed in more detail below, greater 
persistence of cytotoxic SC offers these cells more opportunity to kill cancer cells. Furthermore, 
NSC has been shown to exhibit up to 10-fold higher expression and secretion of therapeutic agents 
compared to MSCs.30,31 Ahmed et al. reported this difference has led to a side-by-side comparison 
in which only NSC therapy provided a significant survival benefit in glioma-bearing mice, 
prolonging survival over 50% compared to controls.30 This suggest that stem cell sources are 
important and needs to carefully considered for the particular application as changes in SCs may 
significantly alter results. 
 
Stem cell migration 
Though in differing amounts, a variety of stem cell types exhibit tumor-tropism.32-35 In 
2000, Aboody et al. demonstrated that NSCs show extensive tumor-tropism towards intracranial 
xenografts.14 These cells are able to home to the primary tumor as well as distant microsatellite 
populations in MB and GBM animal models, suggesting that NSC maybe ideally suited for MB 
and GBM therapy.14,36,37 Also, through systemic administration, NSCs have been shown to migrate 
to tumor sites outside the brain and maintained their migratory capabilities, further establishing 
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their potential as powerful drug delivery vehicles.32,38,39 Through comparative studies, NSC have 
shown to exhibit tumor-tropic migration rates up to 10-fold greater then MSCs.30,40,41 NSCs and 
NSCs generated from cellular reprogramming (e.g. iNSC and iP-NSC) show comparable yet 
significant migration towards gliomas compared to controls in in vitro and in vivo migration 
models.35,42-44  
SCs have demonstrated tumor-homing abilities towards a number of cancer types such as 
brain (GBM and MB), lung, breast, liver, pancreatic and melenoma.45-49 Despite their extensive 
potential as drug delivery vehicles, the molecular mechanisms underlying stem cell tumor tropism 
are largely unknown. Recent studies have implicated stromal-derived neurotrophic factor 1 (SDF-
1) and its cognate receptor CXC-chemokine receptor 4 (CXCR4) as potential intracellular 
mechanism for NSC tumor tropism.33-35,50,51 Other potential signaling pathways linked to NSC 
tumor tropism have been matrix metalloproteinase 1 (MMP1),52 hepatocyte growth factor (HGF),53 
and urokinase-type plasminogen (uPA).54,55 In addition to intracellular mechanisms, pathways 
associated to changes in the tumor microenvironment have been linked to NSC migration such as 
hypoxia-induced factor-1α (HIF-1α)56 and vascular endothelial growth factor (VEGF) 
signaling57,58 which have been broadly implicated in NSC migration. Supplementary to the 
cytokines and growth factors involved in NSC migration, independent investigations have also 
linked insulin growth factor 1 and IL-8/CXCR1 to MSC tumor-tropic migration as determined 
using knockdown studies.59,60 In summary, a wide range of SCs have been proven to exhibit tumor-
tropism. 
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Stem cell administration and persistence 
Effective delivery of therapeutic SCs remain difficult in the treatment of glioma, therefore, 
various methods (intravenous (IV), intranasal (IN), and intratumoral) of SC injections have been 
used to improve stem cell accumulation and persistence as well as treatment efficacy. Though 
systemic delivery is minimally-invasive and has potential to simultaneously treat a number of sites 
within the body, only a limited number of the administered NSCs arrive in the intracranial target 
site.37,61 As another minimally-invasive approach, intranasal delivery has shown sufficient 
intracranial SC accumulation and tumor regression in GBM mouse models but anatomical 
differences between mice and humans lead to questions about the clinical efficacy of this approach 
and whether SCs can accumulate to such an extent in humans.62 Local administration directly 
inside the primary tumor mass is invasive yet has shown success in preclinical settings to 
significantly prolong survival in GBM and MB tumor-bearing mice. This approach has been used 
widely for pre-clinical drug development. Though, this model does not accurately mimic human 
clinical scenarios in which surgical resection is employed.15,37,63-65 Since animal models directly 
affect SC persistence, below we will discuss and summarize that various preclinical brain tumor 
models. 
 
Preclinical brain tumor mouse models 
While surgical resection is a mainstay of GBM standard of care, SCs administered into the 
resulting resection cavity persist for a much shorter period of time than when directly injected in 
to tumor without resection.22,31,66,67 SC persistence varies widely based on cell type. Human MSC 
persist longer than human NSC in the brains of mice as they are known to secrete soluble factors 
that limits immunogenicity and immune rejection.68-71 Furthermore, animal models play a key role 
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in influencing SC persistence. Generally, the more compromised the immune system the longer 
SCs survive in the brain. Human SCs in a mouse brain would experience rapid clearance otherwise. 
Thus SCs administered in brains of nude mice would typically last longer than those in wild-
type.22,31 This is likely consistent within animal models of surgical resection.  
Viable tumor models that mimic post-surgical events are important clinical models as 
surgery plays an important role in the treatment GBM and MB.72,73 Usually studies focus on 
developing genetically similar non-resected pre-clinical models such as established cell line 
allografts (ECLa), established cell line xenografts (ECLx), patient-derived xenografts (PDX), 
genetically engineered mouse (GEM) models, and non-germline genetically engineered mouse 
(nGEM) models.74 ECLa were created by chemical mutagenesis to rodent brain cells that were re-
implanted into the brains of another rodent of similar background. This model is technically 
straightforward to produce, and had high penetrance and uniform in vivo growth kinetics after 
intracranial implantation.75 Though, the genetic landscape of these cells varied widely compared 
to human gliomas, partially as a result of the differences in the process tumorigenesis.76 ECLx 
contained many of the features seen in ECLa, but were more genetically similar to clinical tumors 
as they were isolated from human patients. Though, this model failed to recapitulate important 
histopathological features such as brain invasion.77,78 PDX models overcomes many of the flaws 
connected to ECLx. This is mainly contributed to the low serial culturing as non-adherent cells in 
FBS-free media, preserving the genetic aberrations seen in humans. PDX cells are fresh tumor 
tissue isolated from human patients and inoculated into immune-deficient mice. Also, the 
requirement for immune-compromised host in this model prevents the study of tumor-immune 
system interaction.74,79,80 GEM models were developed to overcome these limitations. These 
models has been to shown to exhibit hallmark features of the clinical disease in immune-competent 
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hosts providing a system to study tumor cell interaction with the immune system.78 Also, this 
model can give temporal control of genetic aberrations through somatic, conditional, and inducible 
systems. Though, unlike in MB models, GBM GEM models generally require complex breeding 
schemes.81-83 In addition, variable penetrance and long tumorigenesis periods limit this approach.74 
To address this issue, nGEM were developed. nGEM utilizes cells harvested from GEM models 
and inoculates them into mice of similar background. This allows for high and uniform penetrance 
as well as spatial control while maintaining the genetic and biological features seen in GEM 
models.84,85 
While GEM models have been studied extensively for preclinical testing for both MB and 
GBM, they have not been utilized in a resection model.86-88 Though, NSC therapy regressed tumor 
volumes in ECLx (U87, U251) and in PDX (GBM4, GBM8) GBM resection models.89-92 Until 
recently (Chapter 2), an intracranial tumor resection model in GEM or nGEM models has yet to 
be created. The lack of spatial control in GEM models will prevent the creation of high-fidelity 
resection models using this system, suggesting nGEM would provide an ideal system for the 
creation of a resection and recurrence model. Furthermore, for MB, there are no previously 
reported resection models (chapter 4). 
Tumor resection produces a biologically harsh environment, creating bleeding that can 
“wash-out” SCs and elicit an immune response.93 In an effort to combat this, synthetic scaffolds 
and biodegradable hydrogels utilizing materials such as hyaluronic acid (HLA),31 fibrin,66 and 
poly-l-lactic acid (PLA)67 have been reported to improve stem cell retention, persistence, 
therapeutic efficacy and median survival. Both HLA and fibrin are degradable biopolymers that 
are malleable and adhere to the walls of the resection cavity. Unlike HLA, fibrin is a naturally 
occurring polymer that plays a role the body’s own wound healing processes. Also, fibrin exhibits 
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a much faster gelation times than its HLA counterpart.31,66,94 Though more cost effective and easier 
to manufacture in large quantities compared to the other approaches, PLA is a material that do not 
readily adhere to tissue surfaces or contain anti-hemolytic properties, limiting their in vivo 
efficacy.67 Therefore, of the three materials, fibrin may be the most ideal to use for cell delivery in 
resected tumor cavities. 
 
Stem cell therapy 
SCs display low levels of intrinsic anti-cancer properties mainly credited to various 
secreted factors95 and physical contact interactions with tumor cells.96 To enhance the anti-tumor 
efficacy, SCs have been genetically modified for cancer therapeutics. The most widely used 
approaches are herein discussed and summarized in table 1.1. 
 
Stem cell therapy- secreted proteins 
Transgenes encoding for secreted proteins that demonstrate potential therapeutic value are 
virally transduced into SCs, either directly or indirectly targeting intracranial tumors. One of the 
most efficacious direct targeting methods involves engineering SCs to express tumor necrosis 
factor-related apoptosis inducing ligand (TRAIL).41,97-99 This ligand binds to death receptors 4 
(DR4) and 5 (DR5) which are almost exclusively expressed in cancer cells, subsequently inducing 
caspase-8-dependent apoptosis as well as decreased tumor growth.100-102 We have previously 
reported NSC therapy engineered to express a secreted variant of TRAIL (s-TRAIL). This allows 
TRAIL to freely diffuse in the extracellular space and bind to its cognate receptor without the steric 
hindrance associated with attachment to the cell surface as in the wild-type protein. In addition, 
creating fusions with TRAIL and bioluminescence imaging markers allows for measuring of 
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pharmacokinetic parameters such as cell clearance. As such, other investigations have fused 
Gaussia luciferase and an optimized secreted variant of Renilla luciferase to s-TRAIL.103 Also, 
NSC have been engineered to express an antagonist of epidermal growth factor receptor variant 3 
(EGFRvIII), a constitutively active EGFR mutant seen in GBM cells, which inhibits EGF-induced 
proliferation of cancer cells.104,105 Interferon-α (IFNα),106 interferon-β (IFNβ),107 interleukin 24 
(IL-24),108and anti- vascular endothelial growth factor receptor (anti-VEGFR)109 antibody have 
been shown to reduce tumor volumes in mouse models of high-grade gliomas. In addition, NSCs 
engineered to express pseudomonas exotoxin-interleukin 13 fusions proteins demonstrated the 
ability to interrupt protein synthesis and cell cycle progression in human GBM in vitro and in vivo 
models.90 For MB, only MSCs expressing s-TRAIL has been used in combination with sensitizers 
and has been shown to exhibit therapeutic efficacy in vitro and in vivo.110,111  
Engineered SCs have also been extensively used to indirectly target glioma cells. SCs 
secreting anti-angiogenic factors such as Thrombospondin 1 (TSP1),112 and PEX (a subunit of 
matrix metalloproteinase 2)113 have reduced tumor growth by inhibiting the formation of blood 
vessels around the tumor. Additionally, GBM and other primary brain tumors are thought to 
suppress the local immune system avoiding potential immune clearance.95,114,115 Therefore, groups 
have engineered SCs to secrete immune modulatory factors such as interleukin 4 (IL-4),116 
interleukin 12 (IL-12),117,118 and interleukin 18 (IL-18)119 in order to counteract tumor-associated 
immune suppression. 
 
Stem cell therapy - enzyme/prodrug 
Suicide gene therapy is another approach for cancer therapeutics. In this approach, SCs are 
engineered to express an enzyme that converts a non-toxic prodrug into its active form, killing 
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neighboring proliferating cells. There are three main enzyme/prodrug pairs: cytosine deaminase 
(CD)/5-fluorocytosine (5-FC), carboxylesterase (CE)/irinotecan, and Herpes simplex virus 
thymidine kinase (TK; also known as HSV-tk)/ganciclovir (GCV). CD converts 5-FC into the 
toxic compound 5-fluorouracil (5-FU), an antimetabolite. Engineered MSCs and NSCs employing 
this therapeutic strategy have been shown to successfully treat GBM in mouse models.120-122 
Additionally, human NSCs expressing CD have been successfully tested in preclinical GBM63 and 
MB123 models and in clinical trials demonstrating the safety of intracranial stem cell therapy for 
GBM. Moreover, along with NSC-CE, NSC-CD have been extensively tested and utilized in non-
GBM and non-MB cancers.37,124,125 In the second major suicide gene therapy, CE converts 
irinotecan into its active metabolite SN-38, a topoisomerase I inhibitor. Human SCs using the 
CE/irinotecan system have been effective in reducing primary GBM tumor volumes in preclinical 
and clinical settings.126-129 Also, the CE/irinotecan system with human NSCs has been used for 
MB in in vitro and in vivo therapeutic efficacy studies.127 In the final suicide gene therapy, TK 
converts the GCV prodrug into mono-phosphorylated GCV, which is additionally modified to the 
cytotoxic compound tri-phosphorylated GCV, a competitive inhibitor of deoxyguanosine 
triphosphate (dGTP).130 This compound primarily targets cancer cells through the bystander and 
distant bystander effects, respectively. Moreover, triphosphorylated-GCV is shuttled to 
neighboring cancer cells via gap junctions, leading to additional cell death.131 Extensive cancer 
cell death primes and recruits anti-cancer immune cells to the tumor, increasing therapeutic 
efficacy. TK/GCV therapy has been effectively used in a number of stem cell types, causing tumor 
regression and extending survival in animal models of GBM and other cancer types.22,66,132  
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Stem cell therapy- oncolytic virus 
In oncolytic viral-therapy, viruses are engineered to infect and preferentially divide in 
cancer cells, causing host cell death and, producing a cycle in which viral progeny infect and lyse 
surrounding tumors cells.133,134 However, this system is limited by numerous drug delivery issues 
such as sufficient accumulation of virus at the tumor and avoidance of the host immune system. In 
order to overcome these challenges, independent laboratories have utilized SCs to deliver oncolytic 
viruses.135-137 NSCs and MSCs delivering viro-therapy have been used locally and systemically in 
GBM mouse models with some success.30,138 The most studied viral-loaded stem cell therapy 
involves oncolytic adenovirus-loaded into NSC. These NSCs selectively accumulated around the 
GBM, leading to tumor regression in GBM animal models.64,139,140 Furthermore, oncolytic 
adenovirus-loaded human NSCs showed selective co-localization at the tumor site, therapeutic 
efficacy and prolonged survival in GBM xenografts.43 Additionally, oncolytic herpes simplex virus 
(oHSV) has also been engineered to provide tumor-selective replication.141 In human trials, this 
system has shown post-operative tumor response but did not significantly extend median survival 
in brain cancer patients,142-144 potentially due to a lack of tissue penetration. Preclinically, MSCs 
loaded with oHSV decreased tumor recurrence, reduced post-surgical tumor burden and prolonged 
survival in glioma-bearing mice.89 
 
Stem cell therapy – nanoparticle delivery 
Nanoparticles (NPs) are widely used because they can overcome drug delivery obstacles 
due to their ability to protect compounds from degradation and enhance therapeutic efficacy. NPs 
can both increase drug dosing to target site and minimize off target effects.145 In addition, their 
surface can be modified with moieties to improve tumor-specific accumulation and 
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pharmacokinetic parameters.146 Typically, NPs fail to cross the BBB and sufficiently accumulate 
intracranially.147,148 In an effort to combat NPs lack of tissue penetration, tumor dissemination, and 
ability to reach cancer cell populations distant from the injection site,149 groups have loaded SCs 
with NPs.149,150 Once loaded, NSCs preferentially migrate towards the primary tumor and 
microsatellite deposits and release the nanoparticle payload.150 Chemotherapy-loaded silica 
“nanorattles” containing doxorubicin have seen tumor specific accumulation and greater 
therapeutic efficacy than non-stem cell-loaded NP controls.151 Also, extracellular-loaded 
polymeric nanoparticles (also known as cellular backpacks) show great potential to safely deliver 
chemotherapy-loaded NPs using NSCs.152,153 Intracellular-loading approaches has also been 
explored with some success.154,155 To control the release kinetics and improve off-target effects, 
some systems contain a light-156, pH-157, or temperature-158 responsive NP release mechanism. 
However, further investigations are needed to determine how NP-loading will influence intrinsic 
stem cell properties and viability. 
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Table 1.1: Genetically modified stem cell therapies for GBM and MB 
Category Therapeutic transgene References 
secreted proteins s-TRAIL 41,97-102 
EGFRvIII 104,105 
PE-/IL-13 90 
IFNα 106 
IFNβ 107 
IL-24 108 
anti-VEGFR 109 
TSP1 112 
PEX 113 
secreted proteins 
(immunomodulatory) 
IL-4 116 
IL-12 117,118 
IL-18 119 
enzyme/prodrug CD (5-FC i.p) 63,120-123 
CE (irinotecan i.v.) 126-129 
TK (GCV i.p.) 22,66,132 
oncolytic viro-
therapy 
oAD 64,139,140 
oHSV 142-144 
Abbreviations: s-TRAIL, secreted variant of tumor necrosis factor-related apoptosis inducing ligand; EGFRvIII, epidermal growth 
factor receptor variant 3; IFNα, interferon-α; IFNβ, IL-24, interleukin 24; PE, pseudomonas exotoxin; IL-13, interleukin 13; 
interferon-β; anti-VEGFR, anti- vascular endothelial growth factor receptor (anti-VEGFR); TSP1, Thrombospondin 1; IL-4, 
interleukin 4; IL-12, interleukin 12; IL-18, interleukin 18; CD, cytosine deaminase; 5-FC, 5-fluorocytosine; i.p, intraperitoneal; i.v, 
intravenous; CE, carboxylesterase; TK, Herpes simplex virus thymidine kinase; GCV, ganciclovir; oAD, oncolytic adenovirus; 
oHSV, oncolytic herpes simplex virus. 
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Stem cell therapy for cancer in clinical trials 
There are three ongoing clinical trials using cytotoxic NSCs for glioma therapy specifically 
for recurrent high-grade gliomas. These trials use an enzyme/prodrug approach utilizing CD/5-FU 
(NCT01172964, NCT02015819) and CE/irinotecan (NCT02192359). The first trial 
(NCT01172964) started with single dose local administration of NSC expressing CD with 
systemic injection of 5-FU. Though therapy was promising, the same group started other clinical 
trials modifying this approach, suggesting the previous study lacked efficacy. The next two studies 
were initiated in parallel. One used multiple stem cell injections (NCT02015819), seemingly to 
improve the effective retained dose at the target site, and the other trial using a more potent 
enzyme/prodrug method (CE/irinotecan; NCT02192359). Since at the time of the first study, there 
were no preclinical models of GBM resection, empirical human testing was necessary to further 
optimize this promising technology. However, since we have developed pre-clinical animal 
models that incorporate surgical resection and exhibit hallmark features of the disease, these 
models can be used for optimization and improved pre-clinical drug development.  
Similarly, SCs have been used for non-glioma cancer indications. These clinical trials 
include MSCs secreting IL-12 against head and neck cancer (NCT02079324) and MSCs infected 
with oncolytic adenovirus for metastatic and refractory solid tumors (NCT01844661). Also, SCs 
are under clinical testing for other non-head or neck cancers. Measles virus encoding the human 
thyroidal sodium iodide symporter-infected MSCs (NCT02068794) and MSC-IFNβ 
(NCT02530047) are in clinical trials for patients with ovarian cancer. 
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Summary 
SCs generated from various sources have been shown to exhibit broad tumor-tropism and 
have been used extensively to treat intracranial neoplasms. These therapeutic agents are apoptotic 
proteins, immune-activating proteins, suicide gene (enzyme/prodrug) approaches, oncolytic viro-
therapy, and nanoparticle delivery. As a result of the preclinical success of treatments utilizing 
SCs, these therapies have been garnering more preclinical investigation and clinical trials. Herein, 
we evaluate the influence of surgery on the residual tumor (Chapter 2), and therapeutic efficacy of 
post-surgical stem cell treatments for GBM (Chapter 3) and MB (Chapter 4) brain tumors. 
Surgical tumor resection is a universal component of the standard treatment regimen for 
GBM patients. Preclinical models fail to mimic this clinical scenario. Instead, preclinical drug 
development is undertaken in solid tumor models that do not incorporate tumor resection. As a 
result, little is known about the post-operative microenvironment and how it may influence tumor 
recurrence. In Chapter 2, we sought to understand how surgical resection potentiates tumor biology 
by developing a GBM resection and recurrence model in mice with a fully intact immune systems. 
. A better understanding of the post-surgical tumor microenvironment will allow development of 
targeted anti-cancer agents that improve surgery-mediated effects on tumor biology. 
There are many challenges with local SC drug delivery to post-surgical GBM tumors. SCs 
injected directly into the surgical walls are ‘washed out’ due to surgery-induced bleeding and 
CSF.31 As a result, cytotoxic SC fail to exhibit a therapeutic effect against the post-surgical GBM. 
In Chapter 3, we fabricate various synthetic extracellular matrix scaffolds that SCs are loaded on 
to improve the in vivo retention and therapeutic efficacy. Using this scaffold technology, we 
provide a method to ameliorate intra-cavity SC delivery issues and improve treatment for GBM 
patients who are receiving SC therapy.  
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MB is the most common primary pediatric brain tumor. Although advancements in 
treatment have improved five-year survival of patients, surgical resection is unable to eradicate 
MB cells and radiation/chemotherapy leaves survivors with debilitating life-long side effects. 
Similar to GBM, little is known about the events following resection as it may reduce therapeutic 
efficacy as previous reports suggests. Cytotoxic NSCs have emerged as a promising approach to 
target aggressive cancers, such as MB, due to their inherent tumor-homing properties. In Chapter 
4, we sought to create the first image-guided MB resection/recurrence mouse model and determine 
whether stem cell therapies would be efficacious against post-surgical MB. If successful, this 
treatment may provide MB patients effective alternative to the standard of care. 
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CHAPTER 2: SURGICAL RESECTION ENHANCES TUMOR AGGRESSIVENESS IN 
A MURINE GLIOMA RESECTION AND RECURRENCE MODEL1 
Introduction 
Glioblastoma (GBM) is the most prevalent and aggressive primary brain tumor and 
portends a poor prognosis.1,159 The current clinical treatment regimen involves surgical resection 
followed by chemo- and radio-therapy.160-162 However, these treatments fail to prevent tumor 
recurrence and median survival remains only 12-15 months.160,163 As surgical resection is central 
to clinical care, a clear understanding of the post-surgical environment and the role that surgery-
induced changes play in mediating tumor response to treatment is vital. It is known that resection 
mediates pathologic changes to residual tumor cells that include increased proliferation, as well as 
enhanced invasion.164,165 Additionally, surgery-related changes to the tumor micro-environment 
have been implicated in reduced effectiveness of local intra-cavity chemotherapy.31 Temporal 
analysis of clinical tissue samples would facilitate the study of these phenomena, yet the rates of 
surgery-related mortality are low for brain cancer patients and few clinical tissue samples are 
available for analysis.8 This makes the use of animal models a necessity, but the mainstay of 
preclinical GBM models remains solid orthotopic human xenografts that fail to incorporate 
surgical tumor resection.166 Thus, preclinical models of GBM resection/recurrence are needed to 
                                                 
1This chapter previously appeared as an article in the journal, Neuro-Oncology. The Original 
citation is as follows: Okolie O et al. Reactive astrocytes potentiate tumor aggressiveness in a 
murine glioma resection and recurrence model. Neuro Oncol, doi:10.1093/neuonc/now117 (2016). 
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understand the post-operative tumor environment and how it may contribute to tumor progression, 
re-growth, or treatment failure. 
Previously, we created an image-guided surgical model of glioma resection and recurrence 
in mice.31,165 In this model, surgical resection of intracranial human GBM xenografts is guided by 
intra-operative fluorescence imaging. Pre- and post-operative multi-modality imaging revealed 
this approach allowed removal of ~92% of the primary mass, followed by rapid recurrence of 
residual GBM cells that displayed a faster growth rate and altered blood-vessel density compared 
to non-resected tumors. Although beneficial, this model fails to address several key aspects of 
clinical GBM resection. First, the use of human xenografts in immune-depleted animals has left 
the role of the immune system entirely unexplored. Immune cells within the tumor 
microenvironment are known to release soluble factors that regulate GBM growth, migration, and 
angiogenesis.167-169 After treatment, tumor cells are thought to hijack components of the host 
immune system and utilize these cells to mediate resistance to chemotherapy and apoptosis, 
increasing malignant tumor progression.170,171 Secondly, our initial studies employed U87 and 
other established GBM cell lines. While the genetics of these extensively cultured cells vastly 
differ from their surgical counterparts, these lines also fail to recapitulate many histological 
hallmarks of GBM, such as the infiltrative growth pattern observed in human patients.74,166 
We have recently described a new genetically engineered murine model of GBM in which 
key signaling pathways were targeted specifically to astrocytes.172-174 These tumor cells, which we 
call TRP, were transformed from cultured astrocytes by inducing aberrations in three of the most 
commonly mutated GBM networks by inactivating the retinoblastoma protein (RB) family of G1/S 
cell cycle proteins (T), activating the Kirsten rat sarcoma viral oncogene homolog (KRAS, R), and 
inactivating the phosphatase and tensin homolog (PTEN) tumor suppressor gene (P). Injection of 
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TRP astrocytes into syngeneic, immune-competent hosts generates GBMs that exhibit infiltrative 
growth patterns and recapitulate aspects of the clinical disease. Engineered TRP allograft models 
accurately recapitulate the full range of histological traits seen in clinical GBMs, including 
elevated mitotic activity, microvascular proliferation, and necrosis. Inoculation of TRP within an 
immune-competent hosts enables both the innate and acquired immune systems present to interact 
with the tumor microenvironment, features that cannot be recapitulated in immune-depleted 
human xenograft models. Together, these features suggest that image-guided micro-surgery of 
TRP allografts could be used to develop more accurate models of GBM. 
In this study, we utilized TRP astrocytes to create a novel model of GBM 
resection/recurrence in immune-competent hosts and sought to characterize the key pathologic 
features of the post-operative surgical cavity. We engineered the TRP model system with optical 
reporters to allow for microsurgical visualization, real-time monitoring of tumor growth, and 
assessment of the biological consequences of tumor resection. We used bioluminescence imaging 
and histology to monitor the pattern of post-surgical tumor recurrence, with a specific focus on 
local tumor growth within the resection cavity, as well as distant growth by invasive tumor cells.  
Finally, we used immunohistochemistry and in vitro co-culture techniques to investigate dynamic 
changes in the reactive astrocyte component of the tumor microenvironment.  
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We found that surgery induces a phenotypic switch in reactive astrocytes into a more 
primitive cell type. Using a model that mimics the in vivo astrocyte response to surgical trauma 
and astrocytes isolated from the in vivo resection model, we found that injury to astrocytes 
promotes tumor proliferation and migration, in vitro. Additionally, through transcriptome and 
secretome analysis, we revealed Cxcl5 may play a key role in this effect. This suggests that 
traumatic brain injury induced by tumor resection alters the local microenvironment and that 
injured astrocytes may impact the aggressiveness of GBM cells adjacent to the surgical cavity.  
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Materials and Methods 
Cell culture 
TRP cells were cultured at 37°C and 5% CO2 in complete media consisting of DMEM 
(Gibco, Grand Island, NY) supplemented with 10% heat-inactivated fetal bovine serum (Sigma, 
St. Louis, MO), penicillin (100 µg/mL, Sigma), and streptomycin (100 µg/mL, Sigma), as 
previously described.174 Primary cortical astrocytes were isolated from 1-4 day old compound TRP 
mice mouse pups harboring a heterozygous floxed TgGZT121 allele (T) encoding an N-terminal 
121-amino acid truncation mutant of SV40 large T antigen (T121), a heterozygous KrasG12D 
floxed knock-in allele (R), and homozygous floxed Pten knock-out alleles (P), all on a C57Bl/6 
background.172-174 Immortalized, non-transformed astrocytes were harvested from T mice. Floxed 
alleles in TRP and immortalized T astrocytes were recombined in vitro with Ad5CMVCre 
(University of Iowa Gene Transfer Vector Core). Lentiviral vectors (LV) engineered to express 
mCherry-Firefly luciferase (LV-mCherry-FLuc) were packaged in 293T/17 cells, as previously 
described.165 TRP cells were transduced with LV-mCherry-FLuc (TRP-mcF) in culture medium 
containing polybrene (6 µg/ml, Sigma). mCherry expression was examined by fluorescence 
microscopy using an Olympus IX2 microscope equipped with a DP72 camera (Center Valley, PA). 
 
Orthotopic allografts and fluorescence-guided microsurgery 
Four to 6 week old female C57/Bl6 mice (Charles River Laboratories, Wilmington, MA) 
were immobilized on a stereotactic frame (Stoelting, Wood Dale, IL) and a 2 cm circular portion 
of skull was removed three days prior to cell injection. TRP-mcF cells were harvested at 80% 
confluency, washed and resuspended in phosphate buffered saline (PBS). 3 × 105 cells per mouse 
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(2 µL) were injected stereotactically in the right frontal lobe at coordinates 2.5 mm lateral to the 
bregma and 0.5 mm deep from dura. 
Mice bearing TRP-mcF allografts established for 14 days and randomized to receive 
surgery (resected cohort, N=8) or not (non-resected cohort, N=13). Mice were anesthetized by 
isoflurane, immobilized on a stereotaxic frame, and placed under an Olympus MVX10 microscope 
for intraoperative fluorescence visualization. The scalp was then excised along the midline and the 
shallow-implanted mCherry+ tumor was visualized. An aspirator was used to perform 
fluorescence-guided microsurgical debulking of the mCherry+ tumor mass. Once the majority of 
the tumor burden was excised, the resection cavity was irrigated with sterile PBS and the scalp 
was closed with surgical glue. Animal studies were approved by the University of North Carolina 
Institutional Animal Care and Use Committee. 
 
Cell growth and migration in vitro 
Growth of TRP and TRP-mcF cells was examined using CellTiter-Glo (Promega, Madison, 
WI) according to the manufacturer’s instructions.  Six replicates of 1,000 cells per well in 96-well 
plates were plated and cell growth was measured at day 0, 1, 3, and 6 by bioluminescence imaging 
(BLI) using an IVIS Kinetic (Perkin Elmer, Waltham, MA) and calculated as luminescence relative 
to day 0. Data (mean ± SEM) were fit to a non-linear exponential growth curve and doubling times 
compared using extra-sum-of-squares F tests. 
To determine whether astrocytes derived directly from the brains of the in vivo surgery 
model would increase the migration of TRP-mcF tumor cells, astrocytes were isolated from the 
resection cavity as previously described.175 Glioma cells (TRP-mcF, GL261, U87, U251; 104 cells) 
and immortalized astrocytes (3x104 cells) or astrocytes derived from the in vivo model (3x104 
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cells) were seeded separately into adjacent wells located 0.5 mm apart in two-chamber culture-
inserts (Ibidi, Verona, WI), placed in glass bottom microwell dishes (MatTek, Ashland, MA) or 
24-well plates, and incubated overnight in complete media. Culture inserts were removed and 
equally spaced vertical (3) and horizontal (4) scratches were performed with a #10 surgical blade 
(Exelint, Los Angeles, CA) to injure each cell population, alone and in combination (N=3 per 
condition). Samples in the glass bottom microwell dishes were placed in a VivaView incubator 
microscope (Olympus) and allowed to equilibrate for 2 hours. Cells were imaged at 10X 
magnification every 20 minutes for 24 hours in 5 random locations per well. ImageJ was used to 
generate movies and single cell analysis (60 cells per condition) was performed using the 
chemotaxis and manual tracking plugin to determine distance, velocity, and directionality of 
migration of TRP-mcF cells, as minimal migration of immortalized astrocytes occurred over this 
time course. Samples in 24-well plates were imaged at 4X magnification at 0 and 24 hours in 3 
random locations per well. ImageJ was used to generate gap closure percent. Data was quantified 
in 2 independent experiments and means (± SEM) were compared using Student’s t-tests.  
To assess proliferation using EdU staining, glioma cells (TRP-mcF, GL261, U251 or U87) 
were co-cultured in 24 well culture plates the presence of scratch injured or uninjured astrocytes 
(N=3 per condition) as described above. Cells were incubated with 10 µM 5-ethynyl-2′-
deoxyuridine (EdU, Invitrogen, Grand Island, NJ) dissolved in medium for 24 hrs. Cells were fixed 
with 4% para-formaldehyde for 10 min and permeabilized with PBS containing 0.1% Triton X-
100 and 1% BSA at 4°C for 30 min. EdU was detected by labeling with Alexa 647 using click 
chemistry. Cells were incubated with a phosphate-buffered reaction buffer containing 4 mM 
copper sulfate, 100 mM ascorbate and 1.6 µM Alexa647-azide (Biotium, Hayward, CA) in the 
dark at 4°C for 30 min. Cells were washed three times with PBS and coverslipped with DAPI-
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containing PermaFluor mounting media (Thermo Scientific, Waltham, MA). Five images were 
taken for each well with an Olympus XI-83 microscope using a 20X objective. EdU+ cells were 
quantified using ImageJ and means (± SEM) compared using Student’s t-tests. 
To assess proliferation of TRP-mcF cells by bioluminescence-based assay, astrocytes were 
grown until 80% confluency in 24-well plate and cells were either scratched or left untreated. 
Twenty-four hrs later, the scratch astrocyte conditioned media (SACM) or control astrocyte 
conditioned media (ACM) was collected. TRP-mcF (six replicates of 500 cells per well in 96-well 
plates) were then treated with SACM or ACM. Cell proliferation was measured by 
bioluminescence imaging (BLI) using an IVIS Kinetic (Perkin Elmer) at day 1, 2, 3, 4, and 7 post-
treatment and expressed relative to photon emission at day 1. Data (mean ± SEM) were fit to a 
non-linear exponential growth curve and doubling times compared using extra-sum-of-squares F 
tests. 
 
BLI and fluorescence immunocytochemistry in vitro 
To determine the correlation between number of transduced cells and bioluminescence 
signal intensity, TRP-mCherry-FLuc cells were seeded in 96-well plates at varying concentrations 
(2x103, 4x103, 6x103, 8x103, 1x104; N = 8 each). Luciferase activity was measured with an IVIS 
Kinetic 5 minutes after adding luciferase substrate (1 µg/mL) and expressed relative to activity in 
104 cells. Data (mean ± SEM) were fit using linear regression. 
To investigate the impact of astrocyte injury on nestin and GFAP expression in vitro, 
immortalized astrocytes were seeded in 24 well plates. After reaching 80% confluency, cells were 
injured, or not, by scratch as described above and incubated for 24 hours. Both control and scratch 
injured cells were fixed with 10% formalin for 10 min at 23°C, blocked with 5% goat serum 
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(Sigma) in PBS (Gibco), and incubated with primary or secondary antibodies diluted in PBS with 
0.05% Triton X-100 (Sigma). Cells were then incubated with GFAP (MAB3402, 2210339, 1:2000, 
Millipore, Temecula, CA) and nestin primary antibodies (MAB353, 2510227, 1:2000, Millipore) 
for 2 h at 23°C, followed by Alexa Fluor 488 dye-conjugated secondary antibody (A-11001, 
1:2000, Invitrogen, Eugene, OR) for 1 h. Cells nuclei were stained with Hoechst and slides were 
cover-slipped using Fluoro-Gel (Electron Microscopy Sciences, Hatfield, PA). Images were 
captured using an Olympus IX2 microscope equipped with a DP72 camera or an Olympus 
Fluoview Confocal FV 1200 inverted microscope. 
 
BLI and survival analysis 
Pre-resection tumor volumes were monitored by BLI using an IVIS Kinetic on day 0, 1, 4, 
7, 10, 14, 16, 20 and 24 following tumor cell implantation. Surgery was performed on day 14 and 
tumor recurrence was monitored on post-operative day 0, 3, 5, 7, and 10 (days 14, 17, 19, 21, and 
24 from cell injection). Images were captured 10 minutes following intraperitoneal injection of D-
luciferin (1 mg per animal in 100 µL of PBS) using a 30 second acquisition time. Bioluminescence 
flux (photons/sec/cm2) was quantified using PerkinElmer LivingImage software and expressed 
relative to mean flux of initial (day 0 pre- and post-resection). Mice were monitored for 
neurological symptoms and sacrificed upon their development. Survival analysis was performed 
as previously described.165 Relative growth was calculated as luminescence increase versus day 0. 
Data (mean ± SEM) were fit to a non-linear exponential growth curve and compared using extra-
sum-of-squares F tests. Survival was evaluated by the Kaplan-Meier method and the effects of 
surgery compared by log-rank tests. 
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Histopathology and immunohistochemistry 
A separate cohort of allograft mice were resected at day 14 after cell injection and 
randomized for sacrifice at day 1, 3, 5, and 7 post-resection (N = 7 each). Mice were anesthetized 
using isofluorane and sacrificed by cervical dislocation. Brains harvested from three mice in each 
cohort were sectioned coronally through the resection cavity, immersion fixed in 10% neutral 
buffered formalin overnight, and stored in 70% ethanol prior to paraffin embedding. Formalin-
fixed, paraffin embedded brains were cut on a rotary microtome in serial 4 μm sections, placed on 
glass slides, and stained with hematoxylin and eosin (H&E) on a Leica Microsystems Autostainer 
XL (Buffalo Grove, IL) in the UNC Translational Pathology Laboratory.  Iba1 
immunohistochemistry was performed as previously described.176 Histopathological analysis and 
grading was performed by CRM according to WHO 2007 criteria for human astrocytomas.177 
Photomicrographs were taken on an Olympus MVX10 or Olympus BX41 microscope equipped 
with a DP71 digital camera. 
Brains harvested from four mice in each cohort were sectioned coronally through the 
resection cavity, immersion fixed in 10% neutral buffered formalin for 3 days at 23°C, embedded 
in OCT (Fischer HealthCare, Houston, TX), and sectioned using a Leica CM1850 cryostat 
(Buffalo Grove, IL). Sections were blocked in PBS supplemented with 5% goat serum (Sigma) 
supplemented PBS (Gibco) and 0.05% Triton X-100 (Sigma) for 30 minutes, and incubated with 
primary antibodies overnight at 4oC. Following incubation, primary antibodies were removed, 
washed with PBS, and incubated with secondary antibody for 2h at room temperature. Sections 
were stained by Hoechst, transferred to microscopy slides, and cover-slipped using Fluoro-Gel. 
GFAP antibody conditions were optimized in a low dilution to selectively detect cells of interest. 
Images were captured using an Olympus Fluoview Confocal FV 1200 inverted microscope or an 
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Olympus IX2 upright microscope equipped with a DP72 camera. Three random images near the 
resection cavity were taken from 3 serial coronal sections per mouse. ImageJ was used to quantify 
the percentage of Hoechst+ cells expressing GFAP or nestin. The mean percent of GFAP+ or 
nestin+ cells ± SEM relative to day 1 post-resection was then calculated from 18-27 images per 
time point. The effects of time were compared using one-way ANOVA with Tukey’s post-test for 
multiple comparisons. 
 
RNA-seq analyses 
Total RNA was extracted from injured or uninjured astrocyte cell pellets using Qiagen 
RNAeasy kits, followed by library preparation using a Stranded mRNA-seq kit (Kapa Biosystems, 
Wilmington, MA) according to the manufacturer's instructions.  High-throughput sequencing with 
75-bp single-end reads was performed on a NextSeq500 using the Illumina High Output kit.  Reads 
were filtered using TagDust and only reads with quality score greater than 20 for 90% of bases 
were retained. Reads were then aligned to the reference mouse genome (mm9) with GSNAP.178,179 
Reads aligning to blacklisted regions of the mouse genome were removed.  Transcript abundance 
was estimated by computing raw counts using RefSeq gene models aggregated by gene symbol. 
For differential expression analyses, raw counts over RefSeq exons were used, then compared 
across samples using DESeq2.180 An adjusted p-value threshold of P < 0.001 was used to identify 
2,093 significant, differentially expressed genes in normal astrocytes exposed to injured versus 
healthy TRP astrocytes. Gene Ontology enrichment using DAVID was performed on significant 
up-regulated genes and identified 65 ontologies.181 Statistically significant ontologies (FDR < 
0.05) were then aggregated using REVIGO and plotted in R.182 
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Luminex analysis 
Protein levels in the supernatant of injured or uninjured astrocytes were determined using 
a mouse magnetic Luminex screening assay (R&D Systems, Minneapolis, MN) according to 
manufacturer’s protocol. The cytokines included in the kit were Cxcl5, Il-33, Tnfsf12/TWEAK, 
and Vegfa. These were analyzed using a Bio-Plex 200 system (Bio-Rad, Hercules, CA) with the 
following detection levels (pg/ml): IL-33 (57.1), Cxcl5 (2.02), TWEAK (0.184), and VEGF (3.96). 
Cultured astrocytes (N = 4 per group) were seeded in 24-well plates overnight and were scratched 
injured or left uninjured as described above. The supernatant of each well was collected and used 
for protein analysis. Each sample was run in duplicate with a 1:2 starting sample dilution. Protein 
concentrations were calculated using standard curves derived from reference standards provide by 
the manufacturer.  
 
Statistical analysis 
Data were analyzed with GraphPad Prism 6 (San Diego, CA). All comparisons were 
considered significant at P<0.05. 
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Results 
Fluorescence-guided microsurgery effectively reduces orthotopic TRP allograft burden, but 
fails to prevent rapid tumor recurrence 
We infected murine TRP cells with a recombinant lentiviral vector encoding mCherry-
FLuc (TRP-mcF) to facilitate high-resolution fluorescence imaging-guided microsurgical tumor 
resection and non-invasive bioluminescence (BLI) to quantify tumor volumes. Fluorescence 
imaging confirmed mCherry expression (Figure 2.1). TRP-mcF cells showed a small, but 
statistically significant decrease in growth compared to uninfected TRP cells (Figure 2.2). 
Dilution assays revealed that the luciferase activity of TRP-mcF correlated directly with cell 
number in vitro (Figure 2.3).  
We have previously shown that TRP allografts develop the histopathological hallmarks of 
human gliomas172 and progress to GBM 15 to 20 days after orthotopic cell injection.174 Similar to 
the parental line, serial BLI showed that engineered TRP-mcF allografts developed into rapidly 
expanding tumors over 24 days in the parenchyma of C57Bl/6 mice (Figure 2.4). Fluorescence 
and histological analysis of post-mortem tissue sections confirmed the presence of large TRP-mcF 
tumors 14 days after injection (Figure 2.5). These tumors contained abundant microvascular 
proliferation and elevated mitotic activity (Figure 2.6), but generally lacked necrosis at this time 
point. These results demonstrate that TRP glioma cells engineered to express mCherry and 
luciferase develop the histopathological hallmarks of human GBM. 
Our previous microsurgical resection model using U87 cells failed to recapitulate important 
hallmarks of clinical GBM, including a full immune system and brain invasion.165 We have 
previously shown that TRP-mcF allografts diffusely invade the brain parenchyma when 
established in syngeneic, immunocompetent mice.174 We therefore examined whether 
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fluorescence-guided microsurgery could be used to resect TRP-mcF allografts that accurately 
reflects the brain-invasive phenotype of human GBM in immune-competent C57 hosts. Fourteen 
days after intra-cortical injection of TRP-mcF cells, mCherry fluorescence was evident in the 
surgical field and was used to guide microsurgical dissection (Figure 2.7). Pre- and post-operative 
BLI showed that resection achieved >90% reduction in tumor burden (Figure 2.8). Histological 
analysis confirmed these findings, as most mice examined displayed only small residual deposits 
of tumor remaining near the resection cavity on post-operative day 1 (Figure 2.9). 
To examine the therapeutic benefit of resection, we monitored TRP-mcF growth before 
and after surgery using BLI. Interestingly, recurrent TRP-mcF tumors grew more rapidly than their 
pre-resection counterparts (Figure 2.10). Similar to clinical findings, resected mice survived 
significantly longer than non-resected mice, but eventually succumbed from their tumor (Figure 
2.11).8,183,184 Fluorescence imaging and histological examination of symptomatic, terminally-aged 
confirmed the presence of recurrent mCherry+ tumors around the resection cavity (Figure 2.12). 
Taken together, these results demonstrate that fluorescence-guided microsurgery can be used to 
create a TRP allograft resection and recurrence model in syngeneic immune-competent host where 
surgery extends the life of mice, but tumor recurrence eventually leads to death. 
We next characterized the peri-tumor microenvironment by performing histological 
analysis of tumor brains 1-7 days after resection to monitor patterns of post-surgical recurrence. 
Histology confirmed near-total tumor resection 1-3 days after microsurgery (Figure 2.13). 
However, despite absence of tumor at the resection cavity, tumor invasion of the deep ipsilateral 
hemisphere led to distant recurrence (Figure 2.13). Recurrent, mitotically active tumors exhibited 
extensive migration along blood vessels and diffusely invaded brain parenchyma (Figure 2.13). 
Five days after tumor microsurgery, locally recurrent tumor became apparent near the resection 
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cavity and was accompanied by reactive changes in the resection bed, including hemosiderin-laden 
macrophages and reactive astrocytes (Figure 2.14). After 7 days, locally recurrent tumors became 
large, highly mitotically active, and necrotic (Figure 2.15) and diffusely invaded the adjacent 
brain. Local tumor recurrence was accompanied by increased reactive changes in the resection 
bed, including infiltration of foamy and hemosiderin-laden macrophages (Figure 2.15). These 
results suggest fluorescence-aided microsurgery in the syngeneic TRP-mcF allograft model system 
recapitulates aspects of clinical GBMs including invasion and distant recurrence, a process that 
occurs concomitantly with reactive, surgery-induced changes in the resection cavity. 
 
Microsurgery induces dynamic changes in the reactive astrocyte component of the peri-
tumor microenvironment surrounding TRP-mcF allografts 
Reactive astrocytes are the main cellular component of glial scars that develop in response 
to a variety of pathological stimuli in the brain. During tumorigenesis, these cells play a key role 
in tumor progression and invasion168,185-188, where they develop hypertrophic cytoplasmic 
processes and up-regulate expression of cytoskeletal proteins such as glial fibrillary acidic protein 
(GFAP). Indeed, hypertrophic, GFAP+ reactive astrocytes accumulated near the invasive edge of 
TRP-mcF allografts and became progressively dense as these tumors grew (Figure 2.16). 
In addition to tumorigenesis, reactive astrocytes are a significant component of the glial 
scars that develop in response to blunt force brain trauma.189-193 In murine models, stab wound 
injury induces proliferation of GFAP+ reactive astrocytes that also express stem cell markers, such 
as the intermediate filament nestin.192,194-196 Moreover, these cells have been shown to acquire the 
phenotypic properties of stem cells when cultured ex vivo, including unlimited self-renewal and 
multi-lineage differentiation.194,195 To determine whether the reactive astrocytes that accompanied 
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TRP-mcF allograft growth might undergo a similar change in phenotype, we performed nestin 
immunostaining on established tumors. In contrast to their abundant GFAP immunoreactivity, 
reactive astrocytes around the invasive edge of TRP-mcF allografts did not express nestin, 
suggesting they lacked stem-like properties (Figure 2.17). 
To examine the effects of blunt force trauma induced by microsurgical resection on reactive 
astrocytes in the peri-tumor microenvironment, mouse brains harvested 1-7 days after resection 
were also immunostained for GFAP and nestin. A dramatic decrease in the number of GFAP+ 
reactive astrocytes were evident over this time course (Figure 2.18). Few of these cells expressed 
nestin at post-operative day 1 (Figure 2.19). However, reactive astrocytes that co-expressed both 
GFAP and nestin (Figure 2.19) increased 16-fold by day 3 and gradually decreased thereafter 
(Figure 2.20). These results suggest that the blunt force trauma induced by resection alters the 
reactive astrocytes present in the peri-tumor microenvironment and may induce a stem cell-like 
phenotype in these cells.194,195 
Because recurrent tumors grew faster than their pre-resection counterparts (Figure 2.10) 
and diffusely infiltrated the brain (Figure 2.13-15), we next used cell culture to explore whether 
astrocyte injury influences tumor biology in vitro. Scratch injury of cultured astrocytes is an 
established in vitro model that mimics the blunt force trauma induced by surgical resection. 
Cultured astrocytes injured by scratching have been shown to undergo a phenotypic switch to a 
stem cell-like state accompanied by increased nestin expression.197-200 We confirmed that scratch 
injury of immortalized astrocytes induces a 2.5-fold increase in nestin expression within 24 hours 
(Figure 2.21). Next, we examined the effects of astrocyte injury on TRP-mcF cell migration and 
proliferation using a co-culture system (Figure 2.22). In contrast to the effects of uninjured 
astrocytes, scratch injury of immortalized astrocytes induced a 2.5-fold increase in migration of 
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co-cultured TRP-mcF cells over 24 hours (Figure 2.22). Astrocytes isolated from the in vivo 
resection model (Figure 2.23) increased TRP-mcF cell migration compared to uninjured 
astrocytes, but showed no difference relative to injured astrocytes (Figure 2.24). In vitro injury to 
astrocytes derived directly from the in vivo model did not increase TRP-mcF migration further. 
Single cell analysis (Figure 2.25) showed the TRP-mcF cells cultured with injured astrocytes 
migrated faster (Figure 2.26), further (Figure 2.27), and more directly towards injured astrocytes 
(Figure 2.28) than those cultured with uninjured astrocytes. These effects were specific to 
astrocyte injury, as scratch wounding of TRP-mcF cells themselves had no effect on their 
migration, in both the presence (Figure 2.29) and absence of injured astrocytes (Figure 2.30). 
Revealing the broad applicability of this effect, astrocyte injury increased migration in established 
GBM mouse (GL261) and human (U251, and U87) cell lines in vitro (Figure 2.31). 
To examine the effects of astrocyte injury on TRP-mcF proliferation, we co-cultured these 
cells with uninjured and injured astrocytes and monitored their proliferation by labeling S-phase 
cells with EdU. Compared to uninjured astrocytes, scratch injury of astrocytes induced 
significantly more TRP-mcF cells to enter S phase after 24 hours of co-culture (Figure 2.32). 
Moreover, culturing TRP-mcF cells with the conditioned media of injured astrocytes increased 
their proliferation as determined by BLI (Figure 2.33). Injured astrocytes increased proliferation 
in both established GBM mouse and human cell lines relative to uninjured astrocytes (Figure 
2.34). Taken together, these data suggest that the blunt force trauma induced by surgical resection 
produces changes in the reactive astrocyte component of the peri-tumor microenvironment that 
may promote tumor migration and proliferation. 
To identify the factors that contribute to the observed tumor proliferation and migration induced 
by astrocyte injury, we performed RNA-seq analysis on cultured astrocytes before and after scratch 
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injury. Differential gene expression analysis (Figure 2.35) and hierarchical clustering (Figure 
2.36) revealed significant alterations to the astrocyte transcriptome after scratch injury. We found 
that injured astrocytes exhibited upregulation of genes involved in cytokine production and 
response (Figure 2.37). Based on RNA-seq analysis, we identified five candidates that were up-
regulated and known to encode secreted proteins (Cxcl5, Il33, Tnfsf12, Tnfsf13, and Vegfa). Four 
of these candidates (Cxcl5, Il33, Tnfsf12, and Vegfa) were examined using Luminex assays, which 
showed that only Cxcl5 was up-regulated in the supernatants of injured astrocytes (1.42-fold, 
P=0074, Figure 2.38). These data suggest Cxcl5 may contribute to increased tumor proliferation 
and migration following astrocyte injury. 
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Discussion 
Surgical resection followed by radio- and chemo-therapy is the standard-of-care for GBM 
patients. Nonetheless, these treatments ultimately fail because they are unable to reach the invasive 
cancer cells that evade surgical resection and lie outside radiation fields.8,183,184 As a result, local 
and regional therapies that penetrate the brain have proven effective, specifically controlled-
release polymers. Others, such as convection-enhanced drug delivery and cell-based therapies, 
hold further promise when used as an adjunct to surgical resection. However, their promise has 
yet to be clinically realized due to the current lack of accurate preclinical models in which to test 
these therapies. To address this gap, we developed a syngeneic, immunocompetent mouse model 
of GBM that mimics the clinical scenario of surgical resection and accurately recapitulates the 
invasive nature of the human disease.172,174 
Surgical resection remains one of the most widely used, yet least studied components of 
GBM therapy. Many of the pathophysiological events following tumor resection remain unknown, 
emphasizing the need for a clinically relevant pre-clinical model. Previous models have used 
human U87 xenografts that fail to recapitulate important GBM features, such as brain 
invasion.31,165,166 In this current study, we developed a resection model that uses glioma cells that 
mimic clinical hallmarks of human GBM in syngeneic immune-competent hosts and exhibits one 
of the most important GBM features, brain invasion. This biologically faithful mouse model 
allowed us to uncover potential mechanisms of tumor progression following tumor resection. 
Thus, this resection model can help provide a better understanding of the pathophysiological 
consequences of surgical resection. 
Reactive astrocytes are recruited to the local microenvironment in response to an 
assortment of pathological stimuli, such as tumor growth168,194,201 and blunt force 
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trauma.190,191,196,202-204 The pattern of reactive astrocytosis after blunt force trauma in the CNS has 
been heavily studied. After cortical stab wound injury, astrocytes react by hypertrophy, up-
regulation of nestin and GFAP, and subsequently dedifferentiate into multipotent cells.192,194,195 
Since glioma resection models are rare, it was unclear how reactive astrocytes in the peri-tumor 
microenvironment would react following traumatic brain injury induced by surgical tumor 
resection. We found that reactive astrocytes express nestin following resection, suggesting that 
these astrocytes dedifferentiate in response to surgical tumor resection. One potential weakness of 
this study is that we used marker expression, instead of ex vivo functional analysis, to suggest 
astrocyte dedifferentiation. However, in a similar context, reports have already shown that 
traumatic brain injury causes astrocytes to acquire stem cell features, including neurosphere 
formation, self-renewal, and multi-lineage potential.194,195 
As a prevalent component of the glioma microenvironment, reactive astrocytes play a 
major role in tumor progression and invasion.167,186,187,205,206 Since our data suggests these 
astrocytes dedifferentiate in response to surgical resection, we further extended these findings by 
investigating how this response may influence tumor biology, specifically, tumor growth and 
migration. Using an in vitro model that mimics the in vivo astrocyte response to injury,197-200,207 
we found the astrocyte response to injury promotes tumor proliferation and migration, suggesting 
that reactive astrocytes may potentiate tumor aggressiveness after resection. Moreover, we found 
that recurrent tumors are highly invasive and exhibited significantly faster growth compared to 
their non-resected counterparts. Since in vitro tumor growth showed marginal increase compared 
to the in vivo response, this suggests reactive astrocytes may only be a contributing factor 
responsible for promoting the increased proliferation of recurrent tumors. Although tumor growth 
and proliferation are more straightforward to monitor, it is difficult to assess in vivo tumor invasion 
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due to mass effects from the malignant tumor. Therefore, surgical tumor resection provided a 
unique opportunity to study tumor cell invasion. While it is challenging to compare the invasion 
of pre- versus post- operative tumors, we found that recurrent tumors extensively invaded the 
brain. Moreover, surgical intervention alters the reactive astrocyte composition within the tumor 
microenvironment and may have deleterious consequences on patient survival. While glioma 
resection remains the standard-of-care in qualified patients, this report highlights the role of 
reactive astrocytes in inducing a more favorable microenvironment for tumor regrowth and 
recurrence. This suggest that our model may provide the means to further understand how the post-
surgical microenvironment influences tumor properties and allow for the development of drugs to 
combat resection-mediated effects. Our data suggests Cxcl5 contributes to increased tumor 
invasion and proliferation after GBM resection, but further experimentation is needed to fully 
characterize and identify the factors responsible for in vivo response. We are currently exploring 
these molecular mechanisms. 
Microglia/macrophages are likely to play an important role in the post-surgical 
microenvironment as tissue scavengers and may potentiate the aggressiveness of recurrent 
tumors.168,208,209 These cells have been implicated in glioma pathogenesis and may promote a 
tumor-permissive microenvironment.210-212 We found that recurrent tumors exhibited a significant 
increase in Iba1+ cells in the tumor compared to pre-resection (Figure 2.39). This suggests that 
microglia/macrophages may play a role in the increased tumor migration and/or proliferation 
observed after resection. 
Surgery alters the tumor microenvironment, which is largely composed of reactive 
astrocytes. The microenvironment in established non-resected tumors contains a high tumor to 
reactive astrocyte ratio while, after tumor resection, recurrent tumors harbor a much lower 
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proportion. Though surgery manipulates the microenvironment, it remains unclear how this effects 
local treatment strategies such as stem cell therapies. Engineered stem cells extensively home to 
glioma cells and have shown therapeutic efficacy.14,213 Though, in a similar context, implanting 
stem cells within a CNS lesion has been shown to reduce stem cell survival, alter differentiation, 
and decrease therapeutic efficacy.31,214 However, the molecular mechanism and signals associated 
with this response remains unclear. To better develop stem cell therapies, we are currently 
investigating the underlying mechanisms that reduce stem cell efficacy in the post-surgical tumor 
microenvironment. 
In conclusion, our study demonstrates the development of a new glioma resection model 
in syngeneic immune-competent hosts that allowed us to study the post-surgical microenvironment 
and pattern of tumor recurrence. We found that surgical resection alters the reactive astrocyte 
component of the peri-tumor microenvironment and injured astrocytes may significantly influence 
tumor biology. Using this study as a template, more investigations can be conducted to gain a 
better understanding of the post-surgical microenvironment. This will allow optimization of 
locally administered therapies and facilitate the development of agents that ameliorate surgery-
mediated effects on tumor properties. 
  
39 
Figures 
 
 
Figure 2.1 – White light and fluorescent images of TRP cells. Cultured TRP glioma cells 
transduced with lentiviral vectors encoding mCherry-FLuc (TRP-mcF) express mCherry and 
luciferase in vitro as determined by white light (A, C) and fluorescence imaging (B, D).  Original 
magnifications: 40X (A, B), 100X (C, D).  Scale bars, 100 µm. 
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Figure 2.2 – In vitro TRP cell growth. TRP-mcF cells (doubling time 1.1 days) showed a small, 
but statistically significant decrease in growth compared to uninfected TRP cells (doubling time 
0.9 days, P=0.01). Data is presented as mean ± SEM. 
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Figure 2.3 – TRP cell number correlation. TRP-mcF cell number showed linear correlation with 
Fluc activity (R2 = 0.998, P<0.0001). Data is presented as mean ± SEM. 
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Figure 2.4 – Bioluminescent images of in vivo tumor growth. TRP-mcF allografts showed 
exponential growth with a doubling time of 3.3 days in vivo by bioluminescence imaging. Data is 
presented as mean ± SEM. 
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Figure 2.5 – H&E and fluorescent images of TRP allografts.  Representative hematoxylin and 
eosin staining (A) and mCherrry fluorescence imaging (B) of brain sections show large intra-
cortical tumors 14 days after injection of TRP-mcF cells. 
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Figure 2.6 – Histopathology of TRP allografts.  Tumors showed histopathological features of 
GBM, including microvascular proliferation (black arrowheads), an invasive brain-tumor interface 
(white arrow), and elevated mitotic activity (white arrowheads).  Original magnifications: 100X 
(A), 200X (B), 400X (C), and 600X (D).  Scale bars, 200 µm. 
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Figure 2.7 - Fluorescence-guided microsurgical resection.  A scalp incision (A) was made 14 
days after injection of TRP-mcF cells. A craniotomy was performed (B) to visualize the underlying 
mCherry+ tumors (C).  Fluorescence-guided microsurgery significantly reduced tumor burden as 
determined by intra-operative fluorescence imaging (D). 
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Figure 2.8 – BLI images and summary graph of pre- and post-resection TRP-mcF allografts. 
Post-operative bioluminescence imaging showed a 91% reduction in mean tumor burden (N=6 
mice per group, P<0.0001). Representative bioluminescence images pre- and post-resection are 
shown. Data is presented as mean ± SEM. 
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Figure 2.9 – Fluorescent and white light images of post-surgical residual tumor. 
Representative mCherry fluorescence (A) and H&E images (B) of brain sections taken 1 day post-
resection showed residual tumor (arrows) within the resection cavity (RC). Original magnification 
100X. Scale bars, 100 µm.  
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Figure 2.10 – In vivo tumor growth of pre- and post-surgical TRP allografts. Recurrent TRP-
mcF allografts grew faster than their pre-resection counterparts, with doubling times of 1.9 vs. 3.3 
days, respectively (P=0.0003). Data is presented as mean ± SEM. 
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Figure 2.11 – Survival benefit of TRP tumor resection. Microsurgical resection extended 
survival, as resected mice survived significantly longer than non-resected mice (31 vs. 21 days, 
log-rank P=0.001). 
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Figure 2.12 – Fluorescent and white light images of recurrent tumors. Fluorescence (A) and 
H&E images (B) of brain sections taken 7 days post-resection shows recurrent tumor near the RC. 
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Figure 2.13 – Hematoxylin and eosin stains of recurrent tumors at day 1 and 3. Representative 
H&E stained sections of mouse brains harvested 1 (A-D), and 3 (E-L) days after resection of TRP-
mcF allografts.  Panels A-H show near-complete resection of tumor around the surgical cavity.  
However, extensive tumor invasion was evident in the deep ipsilateral cortex (I-L) of the mouse 
brain shown in E-H. Original magnifications: 40X (A,E,I), 200X (B,F,K), 400X (C,G,H,J), 600X 
(D,L).  Scale bars = 200 µm. 
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Figure 2.14 – Hematoxylin and eosin stains of recurrent tumors at day 5. Representative H&E 
stained sections of mouse brains harvested 5 days after resection of TRP-mcF allografts.  Panels 
shows local recurrence of tumor within in the resection cavity. Black arrowheads indicate reactive 
astrocytes. White arrowheads indicate hemosiderin laden macrophages. Original magnifications: 
40X (A), 200X (B), 400X (C), 600X (D).  Scale bars = 200 µm. 
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Figure 2.15 – Hematoxylin and eosin stains of recurrent tumors at day 7. Representative H&E 
stained sections of mouse brains harvested 7 days after resection of TRP-mcF allografts.  Panels 
show local recurrence of tumor within in the resection cavity, but also extensive perivascular 
invasion (E, F) and recurrent tumor near the ventricle (A, arrowhead).  Black arrowheads indicate 
mitoses (C, D), foamy macrophages (G) present in recurrent tumors and hemosiderin-laden 
macrophages (H).  Asterisk indicates necrosis (B, C, D).  Original magnifications: 40X (A), 100X 
(E), 200X (B), 400X (C, G, F), 600X (D, H).  Scale bars = 200 µm. 
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Figure 2.16 – Immunohistochemical staining of peri-tumoral astrocytes. Reactive astrocytes 
were abundant in the peri-tumor brain parenchyma in mCherry+ (red) TRP-mcF allografts 
established for 7 days (A) and their density increased further in tumors established for 14 days (B). 
Nuclei are stained with Hoechst (blue). 
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Figure 2.17 – Nestin immunostaining of TRP allografts.  Tumor cells (Red), but not reactive 
astrocytes, expressed nestin (green). Nuclei are stained with Hoechst (blue). 
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Figure 2.18 – Dynamic GFAP changes in reactive astrocytes surrounding TRP-mcF 
allografts. Over the course of 7 days following microsurgical tumor resection, a gradual decrease 
in the density of reactive astrocytes in the peri-tumor microenvironment is highlighted by GFAP 
immunostaining (A-E). All pairwise comparisons in panels E were significant except days 5 and 
7 (P<0.0001). Original magnifications: 100X.  Scale bars = 100 µm. Data is presented as mean ± 
SEM. 
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Figure 2.19 - Dynamic Nestin changes in reactive astrocytes surrounding TRP-mcF 
allografts. Over the 7 day time course, reactive astrocytes gain expression of the stem cell marker 
nestin and their density peaks 3 days post-resection (A-E).  Nuclei are stained with Hoechst (blue, 
A). All pairwise comparisons were significant (P<0.0001). Original magnifications: 100X.  Scale 
bars = 100 µm. Data is presented as mean ± SEM. 
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Figure 2.20 – Nestin and GFAP co-localization in peri-tumoral astrocytes.  Double 
immunostaining of brains 3 days post-resection shows that reactive astrocytes express both GFAP 
(green, B) and nestin (red, C). Nuclei are stained with Hoechst (blue, A). Original magnifications: 
100X.  Scale bars = 100 µm. 
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Figure 2.21 – Nestin stain of uninjured and injured astrocytes. Compared to cultured, 
uninjured astrocytes (A), scratch wounding induces significant increases in nestin (green) 
expression at 24 hours (2.5-fold increase, P<0.0001, B). Nuclei are stained with Hoechst (blue). 
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Figure 2.22 – Injured astrocyte induced TRP cell migration.  Astrocytes and TRP were seeded 
approximately 500 µm apart and groups were constructed with and without scratch injury of each 
cell population (A).  Time-lapse images were captured every 20 mins for 24 hrs and used to 
construct movies that revealed the migration of TPRs in real-time.  Injuring astrocytes by scratch 
induced significantly increased migration of TRP-mcF tumor cells at 24 h (P<0.0001, B). 
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Figure 2.23 – Immunostaining of astrocytes derived from the resection cavity. 
Immunofluorescence analysis of cultured astrocytes harvested from the resection cavity shows co-
expression of GFAP and nestin (A).  No contamination from PDGFRα+ oligodendrocyte 
progenitors (B), Iba1+ microglia/macrophages (C), or NeuN+ neurons (D) was evident in these 
cultures, as all 3 stains were negative.  Positive control staining of cultured murine oligodendrocyte 
progenitors (PDGFRα, E), CRL-2467 microglia (Iba, F), and serum-stimulated neural stem cells 
(NeuN, G) are shown. Nuclei are stained with Hoechst (blue). 
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Figure 2.24 – Astrocyte-induced TRP migration. Astrocytes isolated from the in vivo injury 
model (ExAC uninjured) increased the migration of TRP cells (P=0.0002) and injury in vitro 
(ExAC injured) did not alter migration further (P=0.3). Data is presented as mean ± SEM. 
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Figure 2.25 – Single cell analysis of TRP migration. Single cell imaging analysis showed that 
TRP cells migrate further in the presence of injured astrocytes.  
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Figure 2.26 – TRP migratory velocity after astrocyte injury. Single cell imaging analysis 
showed that injury of co-cultured astrocytes increased the velocity (P<0.0001) of individual TRP-
mcF tumor cells. Data is presented as mean ± SEM. 
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Figure 2.27 – TRP distance traveled after astrocyte injury. Single cell imaging analysis showed 
that injury of co-cultured astrocytes increased the Euclidean distance traveled (P<0.0001) of 
individual TRP-mcF tumor cells. Data is presented as mean ± SEM. 
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Figure 2.28 – TRP directionality after astrocyte injury. Single cell imaging analysis showed 
that injury of co-cultured astrocytes increased the directionality (P<0.0001) of individual TRP-
mcF tumor cells. Data is presented as mean ± SEM. 
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Figure 2.29 – TRP migration in presence of TRP and/or astrocyte injury. Injury to TRP glioma 
cells did not influence their migration either in the presence of astrocyte injury. Data is presented 
as mean ± SEM. 
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Figure 2.30 – TRP migration in the absence of astrocyte injury and/or TRP injury. Injury to 
TRP glioma cells did not influence their migration either in the absence of astrocyte injury. Data 
is presented as mean ± SEM. 
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Figure 2.31 – Astrocyte-induced GBM cell migration. Astrocyte injury induced increased 
migration in established GL261 (P<0.0001), U251 (P<0.0001) and U87 (P<0.0001) GBM cell 
lines. Data is presented as mean ± SEM. 
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Figure 2.32 - Astrocyte-induced GBM cell migration. Compared to uninjured astrocytes, scratch 
injury of immortalized astrocytes increased proliferation of co-cultured TRP-mcF tumor cells 32% 
as measured by EdU incorporation at 24 hours (P<0.0001). Original magnification: 200X. Nuclei 
are stained with Hoechst (blue). Data is presented as mean ± SEM. 
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Figure 2.33 – TRP proliferation in astrocyte conditioned media. TRP-mcF cell proliferation 
was significantly increased when cultured in scratch injured-astrocyte conditioned media (SACM) 
compared to uninjured astrocyte conditioned media (ACM) as measured by BLI (doubling time: 
1.07 vs. 1.19 days, P=0.02). Data is presented as mean ± SEM. 
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Figure 2.34 – Astrocyte-induced GBM cell migration. Scratch injury of astrocytes significantly 
increased proliferation of GL261 (P=0.0006), U251 (P<0.0001) and U87 (P=0.034) GBM cell 
lines (K). Data is presented as mean ± SEM. 
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Figure 2.35 - Astrocyte differential transcriptome expression analysis. Differential expression 
analysis showed that scratch injury of astrocytes  induced significant transcriptome alterations 
(2093 genes, q < 0.001) compared to uninjured astrocytes. 
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Figure 2.36 - Transcriptome-wide changes astrocytes after surgery. Hierarchical clustering of 
gene expression in uninjured (C1-4) versus injured (S1-4) astrocytes shows significant differences 
to the transcriptome.  
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Figure 2.37 – Gene ontology analysis of scratch-induced astrocytes. Ontology analysis of 
upregulated genes revealed enrichment in genes associated with cytokine production and response. 
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Figure 2.38 – Actrocyte secretome analysis. Compared to uninjured astrocytes, astrocyte injury 
increased secretion of Cxcl5 (P=0.0074) as measured by Luminex analysis. **P<0.01 by Student’s 
t test. Data is presented as mean ± SEM. 
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Figure 2.39 - Microglia/macrophage cell recruitment to TRP allografts. Iba1 
immunhistochemical staining of tumor without (left) and 5 days post resection (right) shows 
significant microglia/macrophage infiltration of the resection cavity. 
 
  
78 
 
CHAPTER 3: CYTOTOXIC STEM CELL-LOADED SCAFFOLDS INHIBITS POST- 
SURGICAL GLIOBLASTOMA RECURRENCE2 
Introduction 
 
Glioblastoma (GBM) is the most common primary brain tumor, and one of the deadliest 
forms of cancer.1,215,216 Invasive GBM cells escape into the non-diseased brain, making complete 
surgical resection impossible. Small molecule chemotherapies are unable to reach invasive GBM 
foci. As a result, GBM is incurable and median survival remains only 12-15 months.217 Though 
surgical resection is a universal component of the standard GBM treatment regimen,184 preclinical 
models typically fail to incorporate this clinical scenario. Highlighting the significance of utilizing 
surgical models for preclinical testing, our previous reports found that the post-surgical tumors are 
more aggressive than the pre-resected in an orthotopic GBM resection mouse model.93,165 Thus, 
this creates a more stringent test for drug development as clinical drugs are often used for patients 
with resected GBMs. Therefore, this model can aid in the identification of therapies that are 
effective against post-surgical tumor burdens. 
                                                 
2This chapter previously appeared, in parts, as articles in the journal, Biomaterials, Nature 
Communications, and Science Translational Medicine. The Original citations are as follows: Bagó 
JR et al. Electrospun nanofibrous scaffolds increase the efficacy of stem cell-mediated therapy of 
surgically resected glioblastoma. Biomaterials. 90:116-25 Jun 2016; Bagó JR et al. Fibrin matrices 
enhance the transplant and efficacy of cytotoxic stem cell therapy for post-surgical cancer. 
Biomaterials. 84:42-53 Apr 2016; Bagó JR et al. Therapeutically engineered induced neural stem 
cells are tumor-homing and inhibit progression of glioblastoma. Nat. Comm. 7:10593 Feb 2016; 
Bagó JR et al. Tumor-homing cytotoxic human induced neural stem cells for cancer therapy. Sci. 
Transl. Med., in press. 
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Engineered stem cell (SC) therapies are a promising treatment strategy for GBM.15,136 SCs 
have the unique ability to seek out GBM, migrating to solid and diffuse GBM deposits. A variety 
of preclinical studies have shown that SCs genetically engineered with cytotoxic agents eradicate 
solid GBM tumor deposits and markedly extend survival.15,30,41,45,63,103,108 In the first clinical trials 
using SCs for GBM therapy, the clinicians injected the cells in the walls of the resection cavity. 
Similarly, in in vivo GBM resection models, direct SC implantation into the resection cavity is 
fraught with challenges and results in therapeutic failure.31 There are a number of challenges 
associated with direct cell implantation into the resection cavity as it is limited by obstacles such 
as cellular ‘washout’ from surgery-induced bleeding and cerebral spinal fluid. Synthetic 
biodegradable extracellular matrix (sECM) have been used to improve the retention and the in vivo 
survival of implanted stem cells in other applications.218-221 Thus, sECM technology has the 
potential to improve the retention issue plaguing intra-cavity administration of cytotoxic SC and 
potentially restore their therapeutic efficacy. 
Though, stem cell loaded scaffolds have been used for other application purposes, it has 
been hardly utilized for drug delivery.222-225 Compared to regenerative medicine, the use of cellular 
scaffolds for drug delivery is a brand new field. Since the use of scaffold materials have hardly 
been explored for stem cell therapy, we aim to test a variety scaffolds. We chose 3 off-the-shelf 
materials that have been commonly used for regenerative medicine with the aim for advancing this 
technology to the clinics for cancer therapy.226 Each of the scaffolds have different properties such 
as gelation time, architecture, bioactivity, and mechanical attributes. Poly-L-lactic acid (PLA) is a 
commonly used and FDA-approved material.222,223 PLA sECM can be fabricated to have fibers 
nano- to micrometers thick. These scaffolds can be fabricated with design features that enable 
minimal cross-sectional thickness that could line the walls of the GBM resection cavity. This 
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would permit post-operative fluid to fill the cavity as normal and minimize intracranial pressure 
and mass effect of the sECM. Fibrin is another widely-utilized FDA-approved material. It is 
prepared by the combination of fibrinogen and thrombin proteins, were among the earliest 
biomaterials used to prevent bleeding and create cellular scaffolds. Fibrin is a natural biopolymer 
that forms a scaffold to promote cell attachment during wound healing.227 Unlike slowly forming 
extracellular matrices, fibrin scaffolds rapidly assemble into three-dimensional branching fibers 
following the cleavage of fibrinogen polypeptides by activated thrombin. The biological and 
mechanical properties of fibrin gels have led to their extensive use in clinical patient surgery and 
for a variety of bioengineering applications.228 Hyaluronic acid (HLA), one of the major 
components of the body’s natural extracellular matrix,221 is the only of one of the three chosen 
FDA-approved materials that has been used for stem therapy for GBM.31,90,91 This hydrogel sECM 
improved retention and therapeutic efficacy of implanted stem cells as well as prolonged median 
survival in GBM resection and recurrence mouse model.31 Despite the potential of these 
technologies, it is unknown how each sECM material would influence SC therapy for brain cancer. 
Thus, in this study, we determined the therapeutic efficacy of each sECM material loaded with 
cytotoxic SCs by implanting these compounds into the GBM surgical cavity in murine models. 
To test the therapeutic efficacy of cytotoxic stem cells loaded in various sECM materials 
against post-surgical GBMs, we used novel surgical resection models of GBM in mice and non-
invasive kinetic imaging to measure the therapeutic response of cytotoxic stem cells loaded on the 
three different sECM materials: PLA, fibrin, and HLA. We found that SC-loaded on PLA, fibrin, 
and HLA sECM materials exhibited therapeutic efficacy and extended survival compared to 
controls. As a novel approach to SC therapy, we also utilized induced neural stem cells (iNSCs). 
These cells were directly reprogrammed from skin fibroblasts and engineered to express anti-
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cancer agents. We found that cytotoxic iNSCs were effective against pre-surgical GBMs and 
slowed post-surgical GBM recurrence as well as extended median survival in resection mouse 
models. These results begin to define a new approach to GBM therapy, where sECM scaffolds can 
be designed and fabricated to improve the delivery of local cytotoxic SC therapies to treat post-
surgical GBMs. These findings provide a foundation of incorporating sECM for the improvement 
of clinical stem cell therapies in human patients. 
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Materials and Methods 
 
Cell lines 
U87, LN229 and U251 human glioma cells (American Type Culture Collection) were 
cultured in DMEM (Invitrogen) supplemented with 10% heat-inactivated fetal bovine serum 
(Sigma-Aldrich), 100 µg/mL penicillin (GIBCO), 100 µg/mL streptomycin (GIBCO).103 hMSCs 
were purchased from the Texas A&M MSC Distribution Center (Darwin Prokopf, University of 
Texas A&M). The cells were isolated and characterized according to standard protocols. Briefly, 
hMSCs were isolated from a bone marrow aspirate. Each batch was tested by flow cytometry for 
various cell markers to ensure they are positive for CD105, CD166, CD29, and CD44 but absent 
for expression of CD14, CD34, and CD45. Human fibroblasts were kindly provided by Dr. 
William Kauffman (UNC School of Medicine). All cells were grown as previously described.103,229 
Lentiviral vectors (LV) encoding hTERT and Sox2 were purchased from Addgene (Cambridge. 
MA, USA). All cDNA were under control of the tetracycline promoter. Human iNSCs (h-iNSC) 
were generated following using a single-factor Sox2 and feeder-free method. Briefly, 200,000 
human fibroblasts were seeded in 6-well plates and transduced with the LV cocktail containing 
hTERT and Sox2 in media containing protamine sulfate (5 μg/ml, Sigma Aldrich, St. Louis, MO, 
USA). Two days after infection. The media was changed to STEMdiff Neural Induction Medium 
(StemCell Technologies, Vancouver, Canada) containing doxycycline (10 μg/ml, Sigma). Media 
was changed every 3 days. Neurosphere formation was induced by culturing in low-adherent 
flasks. 
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Lentiviral vectors 
The following lentiviral vectors were used in this study: green fluorescence protein fused 
to firefly luciferase (LV-GFP-FLuc), green fluorescence protein fused to Renilla luciferase (LV-
GFP-RLuc), mCherry protein fused to firefly luciferase (LV-mC-FLuc), a secreted variant of 
TNFα-related apoptosis-inducing ligand (TRAIL, LV-sTR), Gaussia luciferase fused to TRAIL 
(LV-diTR), and a red fluorescent protein Renilla luciferase thymidine kinase fusion (LV-TK; a 
kind gift of Professor S.S Gambhir; Dept. Radiology, Stanford University, USA). GFP-RLuc and 
GFP-FLuc were constructed by amplifying the cDNA encoding Renilla luciferase or firefly 
luciferase using the vectors luciferase-pcDNA3 and pAC-hRLuc (Addgene) respectively. The 
restriction sites were incorporated in the primers, and the resulting fragment was digested with 
BglII and SalI, and ligated in frame in BglII/SalI digested pEGFP-C1 (Clontech, Mountain View, 
CA, USA). The GFP-FLuc or GFP-RLuc fragments were digested with AgeI (blunted) and SalI, 
and ligated into pTK402 (provided by Dr. Tal Kafri, UNC Gene Therapy Center) digested with 
BamHI (blunted) and XhoI to create LV-GFP-FLuc or LV-GFP-RLuc. Similarly, mCFLuc was 
created by amplifying the cDNA encoding firefly luciferase from luciferase-pcDNA3, ligating into 
BglII/SalI digested mCherry-C1 (Clontech), and ligating the mC-FLuc fragment into pTK402 LV 
backbone using blunt/XhoI sites. To create LV-sTR and LV-diTR, the cDNA sequence encoding 
sTR or diTR was PCR amplified using custom-synthesized oligonucleotide templates (Invitrogen, 
Carlsbad, CA, USA). The restriction sites were incorporated into the primers, the resulting 
fragment was digested with BamH1 and XhoI, and ligated in-frame into BamH1/XhoI digested 
pLVX plasmid (a kind gift from Dr. Scott Magness, UNC Department of Medicine, USA). Both 
LV-sTR and LV-diTR have IRES-GFP (internal ribosomal entry sites-green fluorescent protein) 
elements in the backbone as well as CMV-driven puromycin element. All LV constructs were 
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packaged as LV vectors in 293T/17 cells using a helper virus-free packaging system as described 
previously.103,230 GBM, hMSC, and iNSCs were transduced with LVs at varying multiplicity of 
infection (MOI) by incubating virions in a culture medium containing 5 g/ml protamine sulfate 
(Sigma) and cells were visualized for fluorescent protein expression by fluorescence microscopy. 
TISSEEL Fibrin Sealant (Baxter Healthcare Corp., Deerfield, IL, USA) was purchased from the 
University of North Carolina Hospitals and Clinics. 
 
Mouse induced neural stem cell (iNSC) generation 
Mouse iNSCs were generated following the method of Lujan et al.19. 200,000 mouse 
embryonic fibroblasts (MEFs; a kind gift from Dr. Larysa Pevny, UNC) were seeded in 6-well 
plates coated with poly-L ornithine. The MEFs were isolated from C57BL/6J mice at E13.5 and 
utilized at passage number 3. MEFs were transduced with the LV cocktail containing rTTA, and 
Sox2, FoxG1, and Brn2 under the control of the tetracycline inducible promoter in media 
containing polybrene (5 μg/ml, Sigma). Two days after infection the media was changed to N3 
media containing FGF (10 ng/ml, Peprotech), EGF (10 ng/ml, Peprotech), and doxycycline (10 
μg/ml, Sigma)19. Media was changed every 3 days. 
 
Human induced neural stem cell (h-iNSC) generation 
Human iNSCs (h-iNSC) were generated following using a single-factor Sox2 and feeder-free 
method. Briefly, 200,000 human fibroblasts were seeded in 6-well plates and transduced with the LV 
cocktail containing hTERT and Sox2 in media containing protamine sulfate (5 μg/ml, Sigma Aldrich, St. 
Louis, MO, USA).  Two days after infection. The media was changed to STEMdiff Neural Induction 
Medium (StemCell Technologies, Vancouver, Canada) containing doxycycline (10 μg/ml, Sigma). Media 
was changed every 3 days. 
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Scaffold fabrication and seeding 
PLA scaffolds were developed as previously described.231,232 Briefly, PLA (MW= 70000) 
was dissolved in chloroform and dimethylformamide (3:1) (Sigma) at 80oC to create an 11 wt% 
solution. A freshly prepared solution was used in a custom electrospinning system with a grounded 
collector using 15 kV voltage, feed rate of 0.7 µl/hr and spinning distance of 13-15 cm. PLA 
scaffolds were immersed in 70% ethanol for 10 minutes, rinsed several times with PBS, incubated 
in culture medium overnight. The scaffolds were then seeded from 500,000 hMSCs.  
Fibrin patches were created under sterile conditions using Sealer and Thrombin 
preparations from TISSEEL Fibrin Sealant (purchased from the University of North Carolina 
Hospitals and Clinics). To prepare the fibrin scaffolds, eight microliters of Sealer solution (67 – 
106 mg/mL fibrinogen) were mixed with 500,000 hMSCs. Eight microliters of the Thrombin (400 
– 625 units/mL thrombin) preparation was added to initiate gelation and physically mixed using a 
micropipette tip for 30 seconds to create droplets.  
Hyaluronic sECM scaffolds were fabricated as previously described.91 Briefly, to prepare 
h-iNSC loaded hyaluronic scaffolds, hystem and extralink were mixed according to 
manufacturer’s instructions.219 Therapeutic or control h-iNSCs (5×105 cells) were included into 
this mixture and the hyaluronic sECM scaffolds loaded with cells were then loaded into the 
surgical cavity as described below. 
 
Fluorescence-guided tumor resection 
To perform image-guided GBM resection in mice, we modified our previously reported 
strategy.165 Nude mice (6–8 weeks of age; Charles River Laboratories) 25–30 g in weight were 
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used for the intracranial xenograft GBM model. U87-mC-FL or GBM8-mC-FL were harvested at 
80% confluency and implanted stereotactically (5x105 cells) in the right frontal lobe 2 mm lateral 
to the bregma and 0.5 mm from the dura. Following immobilization on a stereotactic frame mice 
were placed under an Olympus MVX-10 microscope connected to a Hamamatsu ORCA 03G CCD 
camera. Intraoperative microscopic white light, GFP, and mCherry images were captured 
throughout the procedure. A midline incision was made in the skin above the skull exposing the 
cranium of the mouse. The intracranial xenograft was identified using mCherry fluorescence. A 
small portion of the skull covering the tumor was surgically removed using a bone drill and forceps 
and the overlying dura was gently peeled back from the cortical surface to expose the tumor.  Under 
mCherry fluorescence, the tumor was surgically excised using a combination of surgical dissection 
and aspiration, and images of mCherry fluorescence were continuously captured to assess accuracy 
of mCherry-guided surgical resection. Following tumor removal, the resulting resection cavity was 
copiously irrigated and the skin closed with 7-0 Vicryl suture. No procedure-related mortality was 
observed.  
 
In vivo GBM therapy 
To study the therapeutic efficacy of NSC and MSC therapy transplant into the resection 
cavity, established orthotopic GBM tumors were resected as described above. Immediately 
following resection, cytotoxic-SC or control-SC (5×105 cells) were transplanted into the post-
operative GBM cavity on one of the various scaffolds. GBM volumes were visualized in the 
therapy and control treatment groups using FLuc imaging as previously described.31 For, h-iNSC-
TK therapy, GCV was dosed daily from day 1 to day 14 post-surgery. Photon emission was 
determined using the IVIS® Kinetic imaging analysis software and expressed expressed as 
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p/sec/cm2/sr relative to day 1. All experimental protocols were approved by the Animal Care and 
Use Committees at The University of North Carolina at Chapel Hill and care of the mice was in 
accordance with the standards set forth by the National Institutes of Health Guide for the Care and 
Use of Laboratory Animals, USDA regulations, and the American Veterinary Medical 
Association. 
 
Tissue processing 
Immediately after the last imaging session, mice were sacrificed, perfused with formalin, 
and brains extracted. The tissue was immediately immersed in formalin. 30 μm coronal sections 
were generated using a vibrating microtome (Fisher). Sections were washed three times with PBS 
and visualized using a confocal microscope (Olympus). In a subset of mice, brains were isolated 
and incubated with or without D-luciferin, and ex vivo whole-brain bioluminescent and fluorescent 
imaging was performed using the IVIS® Kinetic system. 
 
Statistical analysis 
Data were analyzed by Student’s t-test when comparing 2 groups and by ANOVA, 
followed by Dunnett’s post-test when comparing greater than 2 groups. Data were expressed as 
mean ± SEM and differences were considered significant at P<0.05. Survival times of mice groups 
were compared using log-rank test. 
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Results 
 
Intracavity hMSCs loaded on PLA sECM Inhibits Recurrence of Surgically Resected GBM 
The clinical scenario of SC therapy involves cellular implantation within the surgical 
cavity. Previous reports have shown SC injected directly in the resection cavity fails to exhibit a 
therapeutic effect due to surgery-mediated SC retention issues.31 As such, we aimed to test a 
variety of sECM materials to determine whether these scaffolds, which have been shown to 
improve SC retention in regenerative medicine applications,226,228,233  can improve the treatment 
efficacy against post-surgical GBMs. Therefore, we first investigated the effect of human 
mesenchymal stem cells expressing secreted TRAIL (hMSC-sTR) loaded PLA sECMs on post-
surgical GBM in a clinically relevant mouse model of resection (Figure 3.1). Human U87-mC-FL 
were implanted orthotopically into the parenchyma of Nude mice. 10 days later, the GBMs were 
surgically resected using image-guided microsurgery as described above (Figure 3.2). The walls 
of the surgical resection cavity were lined with either hMSC-sTR/PLA or control hMSC/PLA. 
Serial bioluminescence imaging showed GBM recurrence was markedly delayed by hMSC-sTR 
therapy (Figure 3.3). This reduction in GBM volumes was accompanied by a significant extension 
in survival of tumor-bearing animals, as hMSC-sTR-treated mice survived longer than 31 days 
post-therapy compared to only 13.5 days for control-treated animals (Figure 3.4). When taken 
together, our results strongly suggest that hMSC/PLA-based transplant is a highly efficacious 
strategy for intracavity hMSC therapy of surgically resected GBM.  
 
Intracavity hMSCs loaded on fibrin sECM Inhibits Recurrence of Surgically Resected GBM 
To determine the impact of fibrin-encapsulated hMSC-sTR intracavity therapy on post-
surgical GBMs, human GBM cells were xenografted into the parenchyma of mice. One week later, 
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the tumors were surgically resected. Cytotoxic hMSC-sTR or control hMSC were encapsulated in 
fibrin sECM scaffolds and transplanted into the resection cavity (outlined in Figure 3.5). Intra-
operative fluorescent imaging was used to reveal the location of the red fluorescent GBM, guide 
surgical resection, and confirm efficient seeding of hMSC-sTR/fibrin into the resection cavity 
(Figure 3.6). Serial BLI revealed rapid GBM recurrence in control-treated animals, with tumors 
increasing 110-fold in 18 days (Figure 3.7). In contrast, hMSC-sTR/fibrin therapy suppressed 
GBM recurrence 8-fold at 18 days after therapy. Survival analysis revealed the hMSC-sTR/fibrin 
tumor suppression allowed animals to survive more than 36 days after initial treatment (Figure 
3.8). In contrast, control animals succumbed to recurrent GBMs only 15 days. Post-mortem tissue 
analysis revealed the presence of hMSC-sTR in the residual GBM microsatellite foci on the 
boarder of the GBM resection cavity (Figure 3.9). Taken together, our results strongly suggest 
that intracavity hMSC-sTR/fibrin therapy is a highly efficacious treatment for post-surgical 
minimal GBM.  
 
Mouse iNSCs Regress Solid GBM Tumors in Orthotopic Mouse Model 
Although cytotoxic preclinical and clinical testing has relied heavily on allogeneic MSC 
and NSCs, autologous patient-derived NSC therapies could be highly advantageous in clinical use. 
The ability of autologous NSC therapy to avoid immune rejection would not only eliminate the 
complications of immunosuppressive regimens, but could prolong cytotoxic NSC persistence to 
increase both GBM killing and treatment durability. Unfortunately, easy isolation of NSCs remains 
a major challenge45. Reprogramming a patients’ own somatic cells to create autologous cell 
therapies has opened new therapeutic possibilities for cell-based CNS treatment.234 
Transdifferentiation (TD) is the latest advancement in this field and is critically important for cell 
90 
transplant therapies.24 Therefore, using this technology, we generated iNSCs by transducing mouse 
fibroblasts with lentiviral vectors (LV) encoding the transcription factors Brn2, Sox2, and FoxG1 
(Figure 3.10) and genetically engineered these cells with optical reporters (Figure 3.11) and 
therapeutic transgenes (s-TRAIL; sTR).19 To test the in vivo efficacy of iNSC-based therapy, we 
first determined the effects of cytotoxic iNSC treatment on human GBM established cell line 
xenografts. Human U87 GBM cell expressing mC-FL were implanted intracranially with cytotoxic 
or control iNSC. Tumor volumes were followed using serial bioluminescence imaging. We found 
that iNSC-sTR treatment induced a marked reduction in tumor growth and decreased GBM 
volumes 123-fold by day 28 (Figure 3.12). In addition, animals treated with iNSC-sTR survived 
more than 2 months before succumbing to recurrent tumors, while control animal succumbed to 
GBM growth in only 28 days (Figure 3.13). To determine the efficacy of cytotoxic iNSC using a 
more clinically relevant GBM model, we tested these cells against patient-derived human GBM 
xenografts. Serial bioluminescence imaging showed that iNSC-sTR treatment attenuated the 
progression of GBM8 tumors, reducing tumor burden by 18.3-fold compared to control 33 days 
after treatment (Figure 3.14). iNSC therapy also led to a significant extension in survival as 
animals treated with iNSC-sTR survived an average of 59 days compared to only 37 days in 
control-treated mice (Figure 3.15). Together, these results show that cytotoxic iNSC therapy has 
significant therapeutic effects against malignant non-resected GBMs and markedly prolongs the 
survival of tumor-bearing mice. 
 
Intracavity h-iNSCs-loaded on HLA sECM Inhibits Recurrence of Surgically Resected GBM 
Though iNSCs effectively reduced solid GBMs, it remains unknown how well these cells 
would perform against the post-surgical disease and whether human iNSCs (h-iNSCs) exhibit 
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therapeutic efficacy. To determine the therapeutic efficacy of these cells in a model that more 
closely mimics the clinical scenario, we generated and used of human iNSCs expressing thymidine 
kinase (h-iNSC-TK) loaded onto HLA sECM scaffolds in human GBM resection models (Figure 
3.16).31,165 To mimic h-iNSC therapy for surgically resected human GBM patients, invasive 
patient-derived GBM8 cells were implanted into the brain parenchyma of mice (Figure 3.17). Ten 
days later, the established tumors were surgically resected. h-iNSC-TK were encapsulated in HLA, 
transplanted into the surgical resection cavity, and mice were administered GCV or saline. Serial 
BLI showed that h-iNSC-TK+GCV therapy attenuated the re-growth of GBM8 tumors, reducing 
tumor burden by 350% compared to control 14 days after implantation (Figure 3.18). h-iNSC-
TK+GCV therapy also led to a significant extension in survival, as h-iNSC-TK+GCV treated 
animals survived an average of 60 days compared to 46 days in control-treated mice (Figure 3.19). 
Taken together, these findings suggest that therapy using reprogrammed human SCs (h-iNSCs) 
loaded onto sECM materials are effective at delay the progression of post-surgical GBMs and may 
provide an alternative treatment strategy for GBM human patients. 
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Discussion 
Thousands of patients die from brain cancer each year.1,216 Cytotoxic SC therapy is a 
promising new strategy capable of eradicating primary and invasive GBM foci in pre-clinical 
models.15,136,235,236 Developing a strategy capable of retaining cytotoxic SCs within the post-
surgical cavity is essential to preventing GBM recurrence in eventual clinical trials. Synthetic 
extracellular matrix (sECM) materials have been used with success to improve SC retention in 
regenerative medicine applications.94,227,237-239 Here, we examined the therapeutic efficacy of 
cytotoxic SCs loaded on PLA, fibrin, and HLA sECM materials against post-surgical GBM in 
novel resection/recurrence mouse models. We found that cytotoxic SCs loaded on sECM scaffolds 
regressed post-surgical tumor volumes and prolonged median survival 2.3-fold and 2.4-fold for 
PLA and fibrin, respectively. In addition, to create a personalized approach for GBM therapy, we 
found that cytotoxic human iNSCs loaded into HLA sECMs produced over 3-fold reduction in 
GBM tumor volumes and extended survival by 30% in a patient-derived GBM model 
resection/recurrence mouse model. Taken together, these findings reveal that transplanting 
cytotoxic SCs in sECM materials are efficacious against post-surgical GBM and may provide a 
solution to improving SC therapy in human patient testing.  
Since SC therapy in clinical settings are administered in the surgical cavity, we used our 
novel mouse model of GBM resection/recurrence to test SC/sECM technology. We found that 
cytotoxic hMSC loaded PLA sECM therapy delayed the regrowth of post-surgical GBMs and 
significantly inhibited GBM growth within 1 week post-treatment. Cytotoxic hMSC-loaded fibrin 
sECM exhibited similar therapeutic effect as their survival benefit were not significantly different. 
Despite no difference in therapeutic efficacy between SCs loaded on fibrin and PLA sECM, each 
scaffold exhibits attributes that may promote or limit their use in human testing. In contrast to 
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hydrogel scaffolds such as fibrin and HLA, the minimal cross-sectional thickness of PLA is 
advantageous because it should minimize the risk of mass effect and associated morbidity and 
mortality that cavity-filling strategies could cause if the surgical cavity of human patients is filled 
with polymer/SC mixtures. Additionally, the enormous tunability of PLA compared to hydrogels 
should enable fabrication and testing of scaffolds with a wider architecture and composition. 
However, SCs are seeded on the surface of PLA sECM scaffold, not encapsulated such as in fibrin 
strategies. Thus, hydrogel scaffolds such as fibrin and HLA sECM have the capacity to load more 
SCs and as a result have the potential for greater therapeutic efficacy.226,228,240,241 These sECM 
scaffolds are pliable material that would allow reshaping to determine the optimal matrix 
architecture that maximizes SC attributes such as survival, drug release, and migration. These 
scaffolds could increase the clinical utility of this approach and increase the rate of translation into 
human patient testing as it is currently FDA-approved for use in human surgery. Though both HLA 
and fibrin are hydrogel sECM materials, fibrin has a significant advantage. It is a rapidly 
polymerizing matrix that takes several seconds to solidify compared to the several minutes needed 
for HLA. Thus, compared to HLA, fibrin would shorten surgical times in addition to eliminating 
the risk of physical washout of SCs. Furthermore, fibrin has hemostatic properties that aid in 
limiting post-surgical bleeding and potentially improve  patient recovery.228 Based on these data, 
we are currently exploring the optimal scaffold design that maximizes GBM treatment as well as 
other SC parameters such as intra-cavity retention, tumor-directed migration, and anti-GBM 
efficacy as the impact of parameters such as fiber alignment, fiber diameter, composition, fiber 
coating, and degradation rates. This will be critical to maximize the efficacy of cytotoxic stem 
cell/sECM therapy in eventual human patient testing. 
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We sought to utilize next-generation cellular reprogramming to generate easily isolated 
and autologous NSC therapies for GBM therapy. This will avoid immune rejection that could limit 
the tumor killing by allogeneic NSCs currently used in clinical trials. We used transdifferentiation 
(TD) to directly reprogram skin fibroblasts to induced neural stem cells (iNSCs). We found that 
these cytotoxic cells were effective against solid human GBM xenografts. In addition, we used 
human iNSCs engineered to express thymidine kinase (h-iNSC-TK) loaded in HLA sECM 
scaffolds for the treatment of post-surgical GBM.63 In this approach, non-toxic GCV is 
phosphorylated by TK in the h-iNSCs and converted to a toxic compound that diffuses into 
neighboring tumor cells to induce death.242 Using our novel image-guided model of GBM 
resection/recurrence in mice,165 we found that intracavity h-iNSC-TK/HLA treatment suppressed 
the regrowth of patient-derived GBM8 xenografts. Our data showed h-iNSC-TK loaded in HLA 
sECMs were able to kill post-surgical patient-derived GBM8. Since stem cell and scaffold type 
are two of the main factors that influence therapeutic efficacy in this system, the use of different 
stem cell types limit the comparison between sECM materials. Though, our data suggests sECM 
scaffolds can improve the therapeutic efficacy of a broad range of stem cell types. In ongoing 
studies, we are exploring how different sECM influence SC retention, migration and tumor 
therapy.  
In conclusion, the findings of this study reveal that sECM scaffolds are a promising 
approach for local administration of cytotoxic SC for surgically resected GBM. Using a variety of 
GBM resection and recurrence models, we found that cytotoxic MSCs loaded on sECMs inhibited 
post-surgical tumor recurrence and extended survival. In addition, using a personalized medicine 
approach to GBM treatment, we found that cytotoxic mouse iNSC effectively reduced solid tumor 
burdens in GBM xenografts and therapeutic human iNSCs placed on HLA sECMs delayed the 
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recurrence of post-surgical patient-derived GBMs. When. This study provides a foundation for 
further exploration, optimization, and incorporation of sECM scaffolds to improve stem cell 
therapy in clinical trials. In this way, neurosurgeons could deliver the cytotoxic SCs/sECM into 
the resection cavity following GBM removal. Furthermore, this could have broad clinical impact 
to other fields as cytotoxic NSC therapy is being explored for treatment of other surgically treated 
cancers.243,244 
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Figures 
 
 
Figure 3.1 – Illustration of in vivo therapy model of hMSC/PLA implantation. To mimic 
clinical PLA-delivered stem cell therapy for surgically resected GBM, established intracranial 
human GBMs were surgically debulked in mice. Therapeutic stem cells were transplanted into the 
post-operative cavity in PLA patches. 
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Figure 3.2 – Intraoperative fluorescent images of GBM resection and stem cell/PLA 
implantation. Representative images showing pre-resection mCherry+ GBMs, the post-surgical 
GBM cavity, and GFP+ hMSC-sTR in PLA seeded in the resection cavity. The dotted line 
indicates the resection cavity. The arrowheads indicate residual GBM foci. 
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Figure 3.3 – BLI and summary graph of intra-cavity hMSC/PLA therapy. Representative 
images (A) and summary graph (B) of serial BLI showing a significant reduction in GBM regrowth 
in hMSC-sTR-treated animals compared to control-treated (hMSC) animals. Significantly smaller 
tumor volumes were observed in hMSC-sTR-treated tumors across multiple time points. *P<0.01 
by repeated measures ANOVA. Data is presented as mean ± SEM. 
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Figure 3.4 – Survival analysis of intra-cavity cytotoxic hMSC/PLA therapy. Kaplan-Meyer 
survival analysis showing the survival of animals with resected GBMs treated with therapy 
(hMSC-sTR) or control (hMSC) cells. Median survival was 31 days for hMSC-sTR treated 
animals vs. 13.5 days for control-treated mice. *P<0.01 by log-rank test. 
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Figure 3.5 – Illustration of in vivo therapy model of hMSC/fibrin implantation. To mimic 
clinical fibrin-delivered stem cell therapy for surgically resected GBM, established intracranial 
human GBMs were surgically debulked in mice. Therapeutic stem cells were transplanted into the 
post-operative cavity in fibrin patches. 
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Figure 3.6 – Intraoperative fluorescent images of GBM resection and stem cell/fibrin 
implantation. Representative images showing pre-resection mCherry+ GBMs, the post-surgical 
GBM cavity, and GFP+ hMSC-sTR in fibrin seeded in the resection cavity. The dotted line 
indicates the resection cavity. The arrowheads indicate residual GBM foci. 
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Figure 3.7 – BLI and summary graph of intra-cavity hMSC/fibrin therapy. Representative 
images (A) and summary graph (B) of serial BLI showing a significant reduction in GBM regrowth 
in hMSC-sTR-treated animals compared to control-treated animals. Significantly smaller tumor 
volumes were observed in hMSC-sTR-treated tumors across multiple time points compared to 
control-treated (MSC-GFP) animals. *P<0.01 by repeated measures ANOVA. Data is presented 
as mean ± SEM. 
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Figure 3.8 – Survival analysis of intra-cavity cytotoxic hMSC/fibrin therapy. Kaplan-Meyer 
survival analysis showing the survival of animals with resected GBMs treated with hMSC-sTR 
therapy or control hMSC-GFPRLuc. Median survival was 36 days for hMSC-sTR treated animals 
vs. 15 days for control-treated mice. *P<0.01 by log-rank test. 
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Figure 3.9 – Fluorescent images of hMSC within the resection cavity. Fluorescent images of 
post-mortem tissue sections showing the presence of GFP+ hMSCs (green) along the border of the 
recurrent GBM (red). Nuclei were counterstained with Hoechst (blue). Scale bar, 100μm. 
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Figure 3.10 – Schematic of fibroblast conversion to diagnostic and therapeutic iNSCs.  
Illustration of the reprogramming scheme which converts fibroblasts into induced neural stem cells 
that are further engineered into either diagnostic or therapeutic cells. 
 
  
106 
 
Figure 3.11 –Fluorescent image of iNSCs expressing GFP. Cultured iNSCs transduced with 
lentiviral vectors encoding GFP-FLuc (iNSC-GFPFL) express GFP and luciferase in vitro as 
determined by fluorescence imaging.  Original magnifications: 100X.  Scale bar, 100 µm. 
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Figure 3.12 – BLI and summary graph of intra-cavity iNSC therapy against solid GBM. 
Representative images (top) and summary graph (bottom) of serial BLI showing a significant 
reduction in GBM regrowth in iNSC-sTR-treated animals compared to control-treated animals. 
Significantly smaller tumor volumes were observed in iNSC-sTR-treated tumors across multiple 
time points. *P<0.01 by repeated measures ANOVA. Data is presented as mean ± SEM. 
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Figure 3.13 – Survival analysis of cytotoxic iNSCs against solid U87 GBMs.  Kaplan-Meyer 
survival analysis showing the survival of animals with human U87 GBM xenografts treated with 
iNSC-sTR therapy or control iNSC-Control. Median survival was 62 days for iNSC-sTR treated 
animals vs. 28 days for control-treated mice. *P<0.01 by log-rank test. 
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Figure 3.14 – BLI and summary graph of intra-cavity iNSC therapy against patient-derived 
GBMs. Representative images (bottom) and summary graph (top) of serial BLI showing a 
significant reduction in GBM8 tumor regrowth in iNSC-sTR-treated animals compared to control-
treated (iNSC-Control) animals. Significantly smaller tumor volumes were observed in iNSC-
sTR-treated tumors across multiple time points. *P<0.01 by repeated measures ANOVA. Data is 
presented as mean ± SEM. 
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Figure 3.15 – Survival analysis of cytotoxic iNSCs against patient-derived GBM.  Kaplan-
Meyer survival analysis showing the survival of animals with patient-derived GBM8 xenografts 
treated with iNSC-sTR therapy or control iNSC-Control. Median survival was 59 days for iNSC-
sTR treated animals vs. 37 days for control-treated mice. *P<0.01 by log-rank test. 
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Figure 3.16 – Schematic of human fibroblast conversion to therapeutic h-iNSCs.  Illustration 
of the reprogramming scheme which converts human fibroblasts into human induced neural stem 
cells that are further engineered into therapeutic cells. 
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Figure 3.17 – Illustration of in vivo therapy model using h-iNSCs/ HLA. To mimic clinical 
fibrin-delivered stem cell therapy for surgically resected GBM, established intracranial human 
GBMs were surgically debulked in mice. Therapeutic stem cells were transplanted into the post-
operative cavity in fibrin patches. 
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Figure 3.18 – BLI and summary graph of intra-cavity h-iNSC/HLA therapy. Representative 
images (A) and summary graph (B) of serial BLI showing a significant reduction in GBM regrowth 
in h-iNSC-TK+GCV-treated animals compared to control-treated (h-iNSC-TK) animals. 
Significantly smaller tumor volumes were observed in h-iNSC-TK-treated tumors across multiple 
time points. *P<0.01 by repeated measures ANOVA. Data is presented as mean ± SEM. 
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Figure 3.19 – Survival analysis of intra-cavity cytotoxic h-iNSC/HLA therapy. Kaplan-Meyer 
survival analysis showing the survival of animals with resected GBMs treated with therapy (h-
iNSC-TK+GCV) or control (h-iNSC-TK). Median survival was 60 days for treated animals vs. 46 
days for control-treated mice. *P<0.01 by log-rank test. 
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CHAPTER 4: CYTOTOXIC STEM CELL THERAPY INHIBITS POST-SURGICAL 
MEDULLOBLASTOMA IN A NOVEL MOUSE MODELS of 
RESECTION/RECURRENCE3 
Introduction 
 
Medulloblastoma (MB) is the most common primary brain tumor in children.2,245 The 
standard clinical treatment regimen is maximal resection followed by cerebrospinal irradiation 
(CSI) with local boost dose of radiation, and adjuvant multi-drug chemotherapy.246,247 These 
advancements in the clinical treatment regimen have increased the 5-year survival rate to 60-70%,5 
yet their intensive nature causes damage to the developing brain that often leaves survivors 
suffering long-term neurological and developmental defects.4 In the set of children for which MB 
remains fatal, the highly aggressive nature of MB cells allows the cancer to evade surgical 
resection and easily escape chemo-radiation treatment.248,249 There is a significant need to develop 
new therapies that eradicate the residual MB cells that remain after surgery without the adverse 
effects to the non-diseased developing brain caused by current treatment strategies. 
In addition to their regenerative potential, neural stem cells are promising therapies for 
treating cancer.63,136,250,251 NSCs display inherent tumor tropism that allows them to migrate to 
distant and invasive intracranial tumor foci, including malignant gliomas,22,41,103 metastasis from 
systemic cancers, and MB.123,127 Additionally, NSCs can be engineered to deliver a variety of 
                                                 
3This chapter has been prepared as an article and is under submission. The Original citation is as 
follows: Okolie O et al. Intra-Cavity Stem Cell Therapy Targets Post-Surgical Tumor Progression 
in a Novel Orthotopic Medulloblastoma Model. 
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therapeutic agents directly to primary and invasive brain tumors, significantly reducing solid tumor 
volumes and extending the survival of tumor-bearing mice.14,22,31,63,66,123 Although these studies 
suggest NSC therapy could be highly effective against MB, several key hurdles currently limit the 
advancement of NSC therapy into clinical patient testing. One of the most significant barriers 
remains the lack of testing in pre-clinical models that accurately mimic the clinical scenario of MB 
surgical resection. 252-254 Surgical resection is the first line of treatment for human MB patients, 
yet the persistence, fate, migration, and efficacy of cytotoxic NSC therapies against post-operative 
MB is unknown. 
Herein, we utilized human MB cell lines to create the first mouse model of image-guided 
MB resection and recurrence. We then paired this model with both traditional and novel NSC 
carriers to explore multiple aspects of intra-cavity NSC therapy as a new approach to MB 
treatment. We found that real-time, intra-operative, optical imaging allowed resection of 92% of 
MB volumes. Previously, we found that surgical tumor removal causes genetic, molecular, and 
pathologic changes that modify the post-operative tumor into a fundamentally different disease 
than the pre-operative solid neoplasm.93 These surgery-induced changes also have profound effects 
on the delivery and efficacy of stem cell therapies.31,66,67 In the current study, we found that post-
operative MB exhibited triple the growth rate compared to pre-operative, with MB fully re-
developing only 5 days post-surgery. Despite the highly aggressive nature of the post-operative 
cancer, cytotoxic NSCs seeded immediately following tumor resection in the post-operative MB 
cavity markedly suppressed residual tumor volumes and more than doubled the survival of tumor-
bearing mice. As a novel approach to personalized therapy in patients, human induced NSCs 
derived from the skin of pediatric cancer patients were found to migrate to MB, deliver clinically 
relevant therapies that slowed post-surgical MB recurrence, and prolong median survival. These 
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findings provide the first evidence that intra-cavity NSC therapy is an effective treatment for post-
operative MB, and serve as a foundation for advancing this approach towards human patient 
testing. 
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Materials and Methods 
 
Cell culture 
Daoy (ATCC HTB-186), D283 (ATCC HTB-185), C17.2 (NSC) cell lines were cultured 
at 37°C and 5% CO2 in complete media consisting of DMEM (Gibco, Grand Island, NY) 
supplemented with 10% heat-inactivated fetal bovine serum (Sigma, St. Louis, MO), penicillin 
(100 µg/mL, Sigma), and streptomycin (100 µg/mL, Sigma), as previously described.93 Lentiviral 
vectors (LV) engineered to express GFP-Firefly luciferase (LV-GFP-FLuc) were packaged in 
293T/17 cells, as previously described.165 Daoy and D283 cells were transduced with LV-GFP-
FLuc (TRP-GFPFL) in culture medium containing polybrene (6 µg/ml, Sigma). GFP expression 
was examined by fluorescence microscopy using an Olympus IX2 microscope equipped with a 
DP72 camera (Center Valley, PA). 
 
Human pediatric induced neural stem cell generation 
Human pediatric iNSCs (hp-iNSC) were generated using Sox2 under feeder-free 
conditions as described previously.22 Briefly, human pediatric fibroblasts (NHF1-hTERT),255 a gift 
from William Kauffman, were transduced with a Dox-inducible Sox2 lentiviral vector in media 
containing polybrene and cultured in STEMdiff Neural Induction Medium (StemCell 
Technologies, Vancouver, Canada) containing doxycycline (10 μg/ml, Sigma). A week after 
transdifferentiation, these cells were transduced with LV-TK-RFP (hp-iNSCtk) in culture medium 
containing polybrene and visualized as described above. 
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Orthotopic xenografts and fluorescence-guided microsurgery 
Three to four-week old female nude mice (Charles River Laboratories, Wilmington, MA) 
were immobilized on a stereotactic frame (Stoelting, Wood Dale, IL) and a 2 mm circular portion 
of skull was removed three days prior to cell injection. Daoy-GFPFL or D283-GFPFL cells were 
harvested at 80% confluency, washed and resuspended in phosphate-buffered saline (PBS). 1 × 
105 or 1 × 106 cells per mouse (2 µL) were injected stereotactically in the right cerebellum at 
coordinates 4 mm lateral to the midline, 2 mm posterior to the lamboidal suture, and 0.5 mm deep. 
Mice bearing established Daoy-GFPFL or D283-GFPFL xenografts were randomized to receive 
surgery (N=12, Daoy; N=12, D283).  Mice were anesthetized and placed on a stereotaxic frame 
under an Olympus MVX10 microscope for intraoperative fluorescence visualization. After a scalp 
excision along the midline to visualize the underlying GFP+ tumor, an aspirator was used to debulk 
tumor volumes as previously described.165 Bioluminescent imaging was used to measure tumor 
burden pre-resection, immediately post-resection, and at serial time points post-surgery to 
determine growth rate of recurrent tumors. Animal studies were approved by the University of 
North Carolina Institutional Animal Care and Use Committee. 
 
Bioluminescence imaging, in vitro and in vivo 
To determine the correlation between the number of transduced cells and bioluminescence 
signal intensity, Daoy-GFP-FLuc cells were seeded in 96-well plates at varying concentrations 
(2x103, 4x103, 6x103, 8x103, 1x104; N = 6 each). Luciferase activity was measured with an IVIS 
Kinetic 5 minutes after adding luciferase substrate (1 µg/mL). Data (mean ± SEM) were fit using 
linear regression. 
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Pre-resection tumor volumes were monitored by BLI using an IVIS Kinetic on day 0, 14, 
21, 28, 35, 42, and 49 following tumor cell implantation. Surgery was performed on day 49 and 
tumor recurrence was monitored on post-operative day 0, 1, 3, and 5 (days 49, 50, 52, and 54 from 
cell injection). Images were captured 10 minutes following intraperitoneal injection of D-luciferin 
(1 mg per animal in 100 µL of PBS) using a 30 second or one minute acquisition time. 
Bioluminescence flux (photons/sec/cm2) was quantified using PerkinElmer LivingImage software 
and expressed relative to mean flux of initial (day 0 pre-resection). 
 
Histopathology and immunohistochemistry 
Brains harvested from tumor-bearing mice were immersed and fixed in 10% neutral 
buffered formalin overnight, and stored in 70% ethanol prior to paraffin embedding. Formalin-
fixed, paraffin embedded brains were cut in the sagittal plane on a rotary microtome in serial 4 μm 
sections, placed on glass slides, and stained with hematoxylin and eosin (H&E) on a Leica 
Microsystems Autostainer XL (Buffalo Grove, IL) in the UNC Translational Pathology 
Laboratory.  Histopathological analysis was performed by CRM. Photomicrographs were taken on 
an Olympus MVX10 or Olympus BX41 microscope equipped with a DP71 digital camera. 
 
NSC migration to human medulloblastoma in vitro and in vivo 
NSC-mcF (1x104) cells were seeded in the presence or absence of Daoy-GFPFL (1x104) 
cells. Cell populations were separately seeded into adjacent wells located 0.5 mm apart in two-
chamber culture-inserts (Ibidi, Verona, WI), placed in glass bottom microwell dishes (MatTek, 
Ashland, MA), and incubated overnight in complete media. Cells were placed in a VivaView 
incubator microscope (Olympus) and imaged at 10X every 20 minutes for 24 h. ImageJ was used 
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to generate vidoes and single cell analysis to determine distance and velocity of migration of NSCs. 
Data (means ± SEM) were compared using Student’s t-tests.  
To assess the in vivo migratory capability, NSCs (3x106) were injected into the 
contralateral cerebellar hemisphere 7 days after Daoy xenografts wereestablished. Mice brains 
were harvested three weeks after tumor cell implantation, formalin-fixed, sectioned coronally, and 
mounted as described above. Fluorescent images were captured at random locations throughout 
the tumor mass and analyzed using ImageJ. Images were taken with an Olympus IX2 microscope 
equipped with a DP72. 
 
In vitro, and in vivo therapy with Survival Analysis 
To examine the in vitro therapeutic efficacy of thymidine kinase-expressing stem cell 
therapy, human pediatric induced neural stem cells (hp-iNSCtk; 0, 5x102, 1x103, 5x103, 1x104, 
2x104; N = 10 each) or NSCtk (0, 5x102, 1x103, 5x103, 1x104, 2x104; N = 8 each) were cultured 
with D283-GFPFL (1x104 cells) or Daoy-GFPFL (1x104 cells), respectively. Therapeutic response 
was determined 48 hours after Ganciclovir (GCV) administration. Bioluminescent images were 
captured 5 minutes following Luciferin injection using a 10 second exposure. Images were 
processed and analyzed using LivingImage software. 
To assess the in vivo therapeutic efficacy of thymidine kinase-expressing stem cell therapy, 
hp-iNSCtk or NSCtk were implanted into the surgical cavity following microsurgical tumor 
debulking as previously described.66 Twenty-four hours following surgery, mice received systemic 
administration of the prodrug, GCV or remained untreated. Bioluminescent images were taken to 
measure tumor burden and evaluate therapeutic response. Images were captured 10 minutes 
following Luciferin injection using a 1 minute exposure and processed and analyzed using 
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LivingImage software. Mice were monitored for neurological symptoms, sacrificed upon their 
development, and data analyzed as previously described.165  
 
Statistical analysis 
Data were analyzed with GraphPad Prism 6 (San Diego, CA). All comparisons were 
considered significant at P<0.05. Survival was evaluated by the Kaplan-Meier method and the 
effects of treatment compared by log-rank tests. The statistical methods were either ANOVA or t-
test, as appropriate for the data. All figures are presented with variability as means ± SEM. In all 
figures, asterisk indicate level of significance, * < 0.05; ** < 0.01; *** < 0.001; **** < 0.0001.  
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Results 
 
Creating an image-guided model of orthotopic human MB resection and recurrence in mice. 
MB patients typically undergo surgical resection, though preclinical models fail to 
incorporate this clinical aspect. Post-surgical tumors are genetically different than the non-resected 
neoplasm256 and have been shown to exhibit differential response to therapy in other intracranial 
animal models31,93. Thus, we developed an orthotopic MB resection/recurrence model to test our 
therapies against the post-surgical disease. To create the first image-guided mouse model of MB 
resection/recurrence, Daoy human MB cells were transduced with a lentiviral vector encoding a 
bi-modal fusion between GFP and firefly luciferase (Daoy-GFPFL; Figure 4.1). In vitro 
fluorescence imaging confirmed efficient transduction of the cells and high levels of GFP 
expression (Figure 4.1). Dilution assays showed the luciferase activity of the Daoy-GFPFL was 
linearly correlated with cell number (Figure 4.2). We next implanted Daoy-GFPFL into the 
cerebellum of mice to establish orthotopic xenografts. Serial BLI showed gradual growth of the 
tumors (doubling time 5.6 days) that reached 59-fold their original size at day 49 post-implant 
(Figure 4.3). Histological analysis of post-mortem brain tissue confirmed the presence of large 
solid tumors in the cerebellum (Figure 4.4). The tumors demonstrated hallmarks of MB, including 
frequent cell wrapping (white arrowheads) and mitotic division (Figure 4.4; black arrowheads).  
To resect the established MB, we performed craniotomies to expose the underlying 
neoplasm (Figure 4.5). The tumor was then resected using real-time intraoperative fluorescence 
imaging to guide the surgery (Figure 4.5). Fluorescence and white light images confirmed efficient 
debulking of the tumor (Figure 4.7). Pre- and post-resection BLI showed the surgery reduced the 
MB tumor volumes by 92%. Post-mortem visualization of gross brain tissue confirmed generation 
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of a surgical cavity, while histological analysis verified efficient tumor removal with the majority 
of tumor burden near the resection cavity no longer present (Figure 4.8). 
In contrast to the gradual growth of pre-resection tumors, serial BLI showed MB rapidly 
re-developed following resection. Interestingly, post-operative Daoy-GFPFL tumors grew more 
rapidly than their pre-resection counterparts, with doubling times of 5.6 days compared to 1.5 days, 
respectively (P=0.0003; Figure 4.9). Histological analysis confirmed that MB had re-developed 5 
days after surgery as tumors filled the resection cavity (Figure 4.10). Similar to clinical findings,257 
the re-developed tumors were spread throughout the cerebellum (Fig. 2L, M) and disseminated 
through the CSF (Figure 4.10). These results demonstrate that fluorescence-guided microsurgery 
can be used to create an orthotopic MB resection and recurrence model that mimics clinical 
features of the disease. 
 
Neural stem cells migrate towards medulloblastoma cells in vitro and in vivo 
Stem cells have been shown to be powerful tools for brain cancer therapy as their tumor-
homing ability allows them to populate distant tumor foci.14,22,66,89,90 To confirm the tumor homing 
capabilities of NSCs towards MB in vitro and in vivo, we performed real-time motion analysis of 
NSCs co-cultured in the presence or absence of Daoy cells (Figure 4.11, 4.12). We found that 
NSCs randomly migrated when cultured alone, yet NSCs showed rapid and directed migration to 
tumors when MB cells were seeded 500 μm away. Quantitative analysis of migration showed the 
addition of MB increased the rate of NSC migration by 61% (Figure 4.13; P <0.0001) and 
migratory distance by 84% (Figure 4.14; P <0.0001) compared to non-tumor controls. To 
investigate NSC tumor-homing in vivo, we implanted MB xenografts into the cerebellum of mice 
(Figure 4.15). Twenty-one days later, NSCs were implanted in the contra-lateral hemisphere and 
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allowed to migrate for 2 weeks. Using immunofluorescence imaging of post-mortem tissue 
sections, we found NSCs had migrated to the MB, with cells distributed along the tumor-tissue 
interface as well as throughout the core of the tumor (Figure 4.16). This suggests that NSCs 
migrate towards MB cells in the cerebellum. 
 
Cytotoxic NSCs show therapeutic efficacy in vitro and in vivo 
We next investigated a new approach to MB therapy where cytotoxic, tumor-homing 
NSCs, are seeded into the tumor cavity to target the aggressive MB cells that remain after surgery. 
To mimic the NSC prodrug/enzyme therapy in patient testing for adult brain cancer, we engineered 
NSCs to express the enzyme thymidine kinase that leads to tumor kill following administration of 
the pro-drug ganciclovir (NSCtk). Fluorescent imaging of the optical reporter within the cells 
confirmed efficient expression of the construct (Figure 4.17) as well as high transduction 
efficiency (Figure 4.18). To begin exploring intracavity NSCtk therapy, we first explored the 
persistence of therapeutic NSCtk in the post-operative tumor cavity. Established MB were resected 
from the cerebellum and NSCtk were delivered into the post-operative surgical cavity in a fibrin 
matrix (Figure 4.19). Intra-operative white light and fluorescent images confirmed efficient 
seeding of the NSC into the surgical cavity (Figure 4.19). Mice were either administered saline 
(control) or the ganciclovir (GCV) prodrug, and NSC fate was monitored by serial BLI. In the 
control mice, we found the levels of NSCs were not significantly changed through 1 week, yet 
NSC levels in GCV treated mice decreased approximately 90% over 7 days (Figure 4.20).  
MB is divided into 4 distinct molecular subgroups: wnt, sonic hedgehog (Shh), group 3, 
and group 4.258 For evaluating NSC therapeutic efficacy, we utilized the Daoy cell line, which is 
part of the second most common subgroup, Shh.259 Generally, this group is uncommonly 
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metastatic and contains a poor prognosis. Thus, we examined whether NSC therapy can suppress 
post-surgical MB tumor recurrence in vitro and in vivo. To investigate the optimal NSCtk:MB ratio 
needed to induce tumor kill, we co-cultured Daoy-GFPFL cells with serial dilutions of NSCtk 
(Figure 4.21). Luciferase-based viability assays showed that NSCtk induced dose-dependent 
killing of MB cells, with ratios as low as 1:20 leading to a 45% reduction in tumor volume. To 
investigate the in vivo efficacy of NSCtk therapy for post-surgical MB, established Daoy-GFPFL 
xenografts were surgically resected and NSCtk/fibrin were delivered into the resection cavity. 
Serial BLI showed rapid MB recurrence in control mice that did not receive stem cells or in mice 
that did not receive the GCV prodrug (Figure 4.22; no SC and NSCtk). One week after surgery, 
tumor volumes increased 12-fold and animals survived an average of only 8-9 days (Figure 4.22). 
In contrast, activation of therapy by GCV administration significantly inhibited post-operative 
tumor progression. Tumor volumes in the NSCtk/fibrin + GCV group was 20-fold smaller than 
control mice 7 days post-treatment (Figure 4.22; NSCtk/GCV) and median survival more than 
doubled compared to controls (Figure 4.23; 21 vs. 9 days; P <0.0001). Taken together, these 
results provide the first evidence that intra-cavity NSC therapy effectively combat post-surgical 
MB regrowth. 
In human patients, the ideal NSC drug carrier would be easily isolated and autologous to 
avoid immune rejection. Previously, our group utilized next-generation direct reprogramming 
technology to convert skin cells directly into induced neural stem cells (iNSCs). These cells were 
found to home to cancer and deliver therapeutic agents that reduced GBM volumes.22 Although 
this approach could improve MB therapy in human patients, iNSC therapy for pediatric cancer has 
not been explored. To investigate iNSC therapy for MB, we converted human pediatric fibroblasts 
into iNSCs (hp-iNSCs) through overexpression of Sox2, a neural-specific transcription factor, 
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followed by culture in NSC-promoting media.260 After confirming hp-iNSCs expressed markers 
of NSCs, they were then engineered to express thymidine kinase (hp-iNSCtk; Figure 4.24). In vitro 
assays showed these cells exhibited extensive tropism towards MB cells (Figure 4.25, 4.26) and 
migrated over 3-times further when seeded adjacent to tumor cells (Figure 4.27). 
As a stringent test of our hp-iNSCtk therapy, we tested our therapy in a new MB post-
surgical model that utilized the D283 tumor cell line. The genetic profile of this human MB line 
placed it within group 3,261 which is frequently metastatic and contains the worst prognosis of all 
4 subgroups.259 To validate the therapeutic efficacy of hp-NSCtk cells, in vitro co-culture 
experiments revealed that hp-NSCtk efficiently kill D283 MB tumor cells (Figure 4.28). To test 
hp-iNSCtk therapy in vivo, D283 cells engineered to express GFP and firefly luciferase (D283-
GFPFL) were implanted into the brain parenchyma of mice. Once established, the D283 MB were 
surgically resected, hp-iNSCtk were delivered into the post-operative tumor cavity, and mice were 
treated with GCV to activate therapy. Serial imaging of tumor volumes showed that hp-
iNSCtk/GCV therapy suppressed tumor recurrence 332% 11 days after stem cell seeding (Figure 
4.29) and extended median survival compared to control mice (Figure 4.30; 53 vs. 43 days; 
P=0.0004). Post-mortem histological analysis confirmed the presence of large recurrent tumors in 
the control groups and minimal residual tumors in the NSC-treated mice (Figure 4.31), suggesting 
that autologous tumor homing stem cells hold therapeutic potential in patients with MB.  
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Discussion 
 
Medulloblastoma (MB) is the most common childhood brain malignancy with a peak 
incidence at 7 years of age.2 Despite technological advances in the standard of care, nearly all 
patients who survive experience debilitating side-effects.245,246,262 Thus, there is an urgent need to 
minimize the life-changing side effects of treatment or provide alternative therapies.5 To develop 
new therapies and understand current therapies better, we developed a new MB resection and 
recurrence model to determine the impact of surgery on tumor recurrence. Using this model, we 
show that intracavity NSC therapy is effective against MB and may provide a method to control 
the post-operative disease in humans.  
Surgical resection is a universal component of the standard care for MB patients, yet 
surgery remains the least studied part of MB therapy.247 The events following surgical resection 
of MB have not been well explored, but recent studies using glioma models have reported 
increased tumor aggressiveness after surgical resection.31,165 In this study, we revealed that 
recurrent MB tumors exhibited a three-fold increase in proliferation after surgery (Figure 3.9). 
Our model is the first image-guided orthotopic model of MB resection and recurrence and may 
provide the means to further understand the molecular mechanisms of surgery on resulting tumor 
biology, potentially facilitating the development of novel therapeutic agents aimed at resolving 
MB surgery-induced tumor proliferation. 
MB is characterized by the tendency to disseminate into the CSF and spread to other 
regions within the CNS. As a result of the migratory nature of MB, there are numerous drug 
delivery obstacles. NSCs may be an ideal model system for MB therapy, as they have inherent 
tumor-tropic abilities.14,31 In this study, we showed that NSCs migrate towards MB cancer cells in 
vitro and in vivo. NSCs administered in the contralateral cerebellar hemisphere migrated towards 
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and co-localized with established MB tumors. Consistent with other reports,123 this suggests NSCs 
display tropism towards MB. The ability of NSCs to migrate long distance and populate distant 
foci is likely dependent on their ability to persist in the brain. We found that NSCs persist for 1 
week after prodrug injection, providing a limited window in which they can migrate to MB cancer 
cells. This limited persistence could reduce their ability to reach distant or metastatic sites, 
particularly as this approach is scaled to human patients. In the current study, we only explored 
GCV administration at 24 h after NSC implantation, but prodrug administration could be delayed 
to provide longer time for NSC homing. Currently, we are exploring this and other strategies to 
increase the time therapeutic stem cells have to reach tumor cells that are in distant locations and/or 
spread within the CSF and spinal cord.  
Genetically engineered NSCs that express cytotoxic agents are non-toxic, significantly 
diminish tumor burden and extend survival in orthotopic mouse models of malignant 
gliomas.41,63,103,108,136,263 NSCs have been extensively utilized to treat post-surgical glioblastoma, 
22,31,66,67,90-92 but have not been explored in an orthotopic MB resection model. In this study, we 
showed that intra-cavity cytotoxic NSCs were effective against MB.  We tested our therapy in two 
genetically distinct MB tumor models (D283 and Daoy) that mimic different molecular and clinical 
phenotypes. Daoy is part of the sonic hedgehog (SHH) subgroup that contain a poor clinical 
prognosis. Using NSC therapy, we improved survival by more than two-fold compared to controls. 
D283 is a group 3 tumor that is very frequently metastatic and has the poorest prognosis of all MB 
subgroups. Using our cytotoxic NSCs derived from human pediatric fibroblasts, hp-iNSCtk therapy 
suppressed tumor growth and extended median survival in this aggressive tumor type. Taken 
together, this demonstrates NSC therapy is effective against a variety of MB subgroups with 
different clinical phenotypes. 
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Most preclinical and clinical studies use allogeneic NSCs, but autologous cells may be 
beneficial because they evade immune rejection and persist longer, thus increasing tumor treatment 
and durability.264,265 Cellular reprograming has led to many technological advances in cell-based 
therapies. The cells of a patient can be reprogrammed to create autologous cells for personalized 
medicine.234 Transdifferentiation (TD), the latest advancement in the reprogramming field, has 
allowed for quick and efficient cell type transitions.24 Unlike in pluripotent reprogramming, TD 
does this conversion directly without passing through an undifferentiated pluripotent state, 
therefore bypassing some concerns that reprogrammed cells or their derivatives could reactivate 
the oncogenes and form cancerous teratomas in vivo. The added safety benefit makes TD-derived 
NSCs an ideal source for cell-based therapy for MB. By using skin fibroblasts as a source of cells 
for transdifferentiation, we can generate human induced neural stem cells (hp-iNSCs) in a matter 
of days.260,266 In addition, fibroblasts obtained from young individuals are more readily 
reprogrammed,267,268 suggesting this approach may be well suited for pediatric cancers, such as 
MB. However, this is the first study in which the tumor-homing migration and therapeutic efficacy 
of these cells or wild-type NSCs has been explored for MB treatment as well as the only study that 
tests stem cell therapies in a cerebellar resection/recurrence tumor model. Our data demonstrates 
that cytotoxic hp-iNSCs home to MB cells in vitro, and suppresses tumor growth and extends 
median survival in MB resection and recurrence mouse model. Though stem cell therapy was 
effective against post-surgical MB, tumors eventually re-developed and led to death. Therefore, in 
future studies, concomitant treatment of cytotoxic hp-iNSCs with synergistic therapies directed 
against pathways driving resistance may provide an effective method to prolong treatment 
durability and eliminate therapy-resistant cell populations. 
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In conclusion, our study outlines the development of a novel MB resection model that 
allowed us to test traditional and clinically-relevant stem cell therapies derived from human 
pediatric skin cells. Similar to the clinical disease, MB xenografts exhibit aggressive properties as 
they were shown spread to the cerebrum and disseminate through the CSF. Also, we found that 
recurrent tumors grow significantly faster than non-resected tumors, providing obstacles for 
effective tumor treatment. We discovered cytotoxic NSCs migrate towards MB cancer cells in 
vitro and through the cerebellum in vivo. Both cytotoxic brain-derived NSCs and hp-iNSCs 
derived from pediatric fibroblasts were effective at regressing post-surgical tumors and 
significantly extended survival in mice. This study should provide a foundation for development 
of cytotoxic NSC therapies that home towards MB cancer cells and diminish MB in human 
patients. 
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Figures 
 
 
Figure 4.1 – White light and fluorescent images of Daoy cells. Cultured Daoy medulloblastoma 
cells transduced with lentiviral vectors encoding GFP-FLuc (Daoy-GFPFL) express GFP and 
luciferase in vitro as determined by white light (A, B) and fluorescence imaging (C, D).  Original 
magnifications: 40X (A, C), 100X (B, D).  Scale bars, 100 µm. 
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Figure 4.2 – Daoy cell number correlation. Daoy-GFPFL cell number showed linear correlation 
with Fluc activity (R2 = 0.978, P=0.001). Data is presented as mean ± SEM. 
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Figure 4.3 – Bioluminescent images of in vivo tumor growth. Daoy-GFPFL xenografts showed 
exponential growth with a doubling time of 5.6 days in vivo by bioluminescence imaging. Data is 
presented as mean ± SEM. 
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Figure 4.4 – Histopathology of Daoy xenografts.  Tumors showed histopathological features of 
MB, including frequent cell wrapping (white arrowheads) and heightened level of mitosis (black 
arrowheads).  Original magnifications: 15X (A), 200X (B), 400X (C), and 600X (D).  Scale bars, 
200 µm. 
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Figure 4.5 – Fluorescence-guided microsurgical resection.  A scalp incision was made 49 days 
after injection of Daoy-GFPFL cells. A craniotomy was performed (A) to visualize the underlying 
GFP+ tumors (B).  Fluorescence-guided microsurgery significantly reduced tumor burden as 
determined by intra-operative white-light (C) and fluorescence imaging (D). 
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Figure 4.6 – BLI images and summary graph of pre- and post-resection Daoy-GFPFL 
xenografts. Post-operative bioluminescence imaging showed a 92% reduction in mean tumor 
burden (P=0.009). Representative bioluminescence images pre- and post-resection are shown. 
***P<0.001 by Student’s t test. Data is presented as mean ± SEM. 
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Figure 4.7 – White light image of tumor-bearing brains pre- and post-resection.  
Representative white-light images demonstrating the amount of brain tissue removed in the 
cerebellum after surgical resection. 
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Figure 4.8 – H&E images of the post-surgical cavity. Representative H&E images  of brain 
sections taken immediately post-resection did not show apparent residual tumor within the 
resection cavity. Original magnifications: 15X (A), 200X (B), 400X (C), and 600X (D).  Scale 
bars, 200 µm. 
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Figure 4.9 – In vivo tumor growth of pre- and post-surgical Daoy xenografts. Recurrent Daoy-
GFPFL xenografts grew faster than their pre-resection counterparts, with doubling times of 1.5 vs. 
5.6 days, respectively (P=0.0003). Data is presented as mean ± SEM. 
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Figure 4.10 – Hematoxylin and eosin stains of recurrent tumors at day 5. Representative H&E 
stained sections of mouse brains harvested 5 days after resection of Daoy-GFPFL xenografts.  
Panels shows local recurrence of tumor within in the resection cavity (A, B) and cancer cells 
invading the fourth ventricle (C). Original magnifications: 40X (A), 400X (C), and 600X (B).  
Scale bars = 200 µm. 
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Figure 4.11 – In vitro NSC migration towards Daoy cancer cells. NSCs were seeded in the 
presence or absence of Daoy cells physically separated approximately 500 µm apart.  Time-lapse 
images were captured every 20 mins for 24 hrs and used to construct movies that revealed the 
migration of NSCs in real-time. 
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Figure 4.12 – Single cell analysis of NSC migration. Single cell imaging analysis showed that 
NSCs migrate further in the presence of Daoy cells. 
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Figure 4.13 – NSC migratory velocity in the presence of Daoy cells. Single cell imaging 
analysis showed that the presence of co-cultured Daoy cells increased the velocity (1.61-fold; 
P<0.0001) of individual NSCs compared to the control. ****P<0.0001 by Student’s t test. Data is 
presented as mean ± SEM. 
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Figure 4.14 – NSC distance traveled in the presence of Daoy cells.  Single cell imaging analysis 
showed that the presence of co-cultured Daoy cells increased the migratory distance (1.8-fold; 
P<0.0001) of individual NSCs. ****P<0.0001 by Student’s t test. Data is presented as mean ± 
SEM. 
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Figure 4.15 – In vivo migration scheme of NSCs to Daoy xenografts. Illustration of the 
experimental scheme showing NSC and Daoy-GFPFL cells were implanted in opposite cerebellar 
hemispheres and allowed to migrate. 
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Figure 4.16 – In vivo NSC migration towards Daoy xenografts. Fluorescent images taken 21 
days after stem cell implantation shows NSCs co-localize with Daoy-GFPFL tumor cells (A, B, 
C). 
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Figure 4.17 – White light and fluorescent images of NSCtk cells. Cultured NSC cells transduced 
with lentiviral vector encoding thymidine kinase (NSCtk) as determined by white light (A) and 
fluorescence imaging (B).  Original magnifications: 100X.  Scale bars, 100 µm. 
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Figure 4.18 – White light and fluorescent images of NSCtk cells loaded in fibrin matrix, in 
vitro.  White light and fluorescent images of NSC expressing TK are shown mixed with fibrin 
matrix.  Original magnifications: 40X.  Scale bars, 100 µm. 
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Figure 4.19 – White light and fluorescent images of NSCtk cells loaded in fibrin matrix, in 
vivo.  Illustration of the in vivo therapy scheme which shows tumors are grafted within the 
cerebellum, resected and drugged with therapeutic stem cells (A).  Representative white light (B) 
and fluorescent (C) images show NSCtk/fibrin implanted within the resection cavity. 
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Figure 4.20 – In vivo persistence of NSCtk cells. NSCtk persist longer in the brain without 
systemic administration of Ganciclovir (-GCV) compared to with (+GCV).  Representative BLI 
images of each group day 3 and 7 post-surgery are shown above. *P<0.05 by repeated measures 
ANOVA. Data is presented as mean ± SEM. 
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Figure 4.21 – NSCtk therapy, in vitro. Daoy-GFPFL cells were seeded with varying 
concentrations of NSCtk cells.  Tumor cell viability was measured by luminescence 24h after GCV 
administration. *P<0.05 by one-way ANOVA. Data is presented as mean ± SEM. 
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Figure 4.22 – NSCtk therapy, in vivo. Summary graph and representative BLI images showing a 
significant reduction of tumor burden in NSCtk/GCV-treated mice compared to control-treated (no 
SC and NSCtk). *P<0.05 by repeated measures ANOVA. Data is presented as mean ± SEM. 
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Figure 4.23 – Survival benefit of NSCtk therapy. Cytotoxic stem cell treatment extended median 
survival, as treated mice survived over two-fold longer compared to controls (9 vs. 21 days, log 
rank P<0.0001). *P<0.05 by log-rank test. Data is presented as mean ± SEM. 
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Figure 4.24 – Fluorescent images of human pediatric induced neural stem cells expressing 
thymidine kinase.  Illustration of the reprogramming scheme which converts human pediatric 
fibroblasts into cytotoxic human pediatric-induced neural stem cells (hp-iNSCtk;A). Hp-iNSC 
express the thymidine kinase/RFP lentiviral vector as determined by white light fluorescent images 
(B, C). Original magnifications: 40X (B), and 100X (C).  Scale bars, 100 µm. 
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Figure 4.25 – Illustration of hp-iNSC in vitro migration towards D283.  Schematic depiction 
of hp-iNSCtk migration assay in the presence (+D283) or absence (control) of tumor cells. 
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Figure 4.26 – hp-iNSC in vitro migration towards D283. Hp-iNSC cells were seeded in the 
presence or absence of D283-GFPFL cells and tracked over the course of 24h by fluorescent and 
white light imaging.  Original magnifications: 100X.  Scale bars, 100 µm. 
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Figure 4.27 – hp-iNSC distance traveled in the presence of D283 cells.  Summary graph shows 
hp-NSCtk cells migrate further in the presence D283-GFPFL cells (3.3-fold, P < 0001). 
****P<0.0001 by Student’s t test. Data is presented as mean ± SEM. 
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Figure 4.28 – hp-iNSCtk therapy, in vitro. D283-GFPFL cells were seeded with varying 
concentrations of hp-iNSCtk cells.  Tumor cell viability was measured by luminescence 24h after 
GCV administration. *P<0.05 by one-way ANOVA. Data is presented as mean ± SEM. 
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Figure 4.29 – hp-iNSCtk therapy, in vivo. Representative BLI images (A) and summary graph 
(B) showing the in vivo therapeutic efficacy of cytotoxic NSC therapy (hp-iNSCtk/GCV) compared 
to control (hp-iNSCtk). *P<0.05 by repeated measures ANOVA. Data is presented as mean ± SEM. 
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Figure 4.30 – Survival benefit of hp-NSCtk therapy. Stem cell therapy extended survival, as hp-
iNSCtk/GCV survived significantly longer than their control counterparts (53 vs. 43 days; 
P=0.0004). *P<0.05 by log-rank test. 
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Figure 4.31 – Histopathology of D283 xenografts following therapy.  Histopathological 
analysis showed the presence of large recurrent tumors in control mice (A) and minimal residual 
tumor in the treatment (B) groups.  Original magnifications: 200X.  Scale bar, 100 µm. 
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CONCLUSIONS/FUTURE DIRECTIONS 
 
Aggressive brain tumors such as GBM and MB, contain dismal prognosis.1,2,4,8,160 Standard 
treatment regimens fail to reach distant tumor cells and prevent recurrence. In addition, patients 
and especially children who survive experience life-long side effects secondary to treatment.269 
Though, surgery is a universal component of the standard of care for these diseases, little is known 
about how it may affect tumor progression or therapeutic efficacy. To address this gap, we 
developed in vivo models of GBM and MB that mimics the clinical scenario of surgical resection 
and accurately recapitulates the invasive nature of the human disease. In addition, we utilized this 
model to test our local cytotoxic stem cell therapies. Stem cells extensively home towards cancer 
cells, establishing these cells as ideal tools to target invasive intracranial tumors. 
In Chapter 2, we developed a new model of glioma resection model in syngeneic immune-
competent hosts that allowed us to study the post-surgical microenvironment and pattern of tumor 
recurrence. We found that surgical resection alters the cellular component of the peri-tumor 
microenvironment, specifically the reactive astrocyte portion. After, in vitro and in vivo modeling 
revealed that these injured astrocytes may significantly influence tumor biology by potentiating 
tumor proliferation as well as migration. Using this investigation as the foundation, more studies 
can be conducted to gain a better understanding of the post-surgical microenvironment and how it 
influences intra-cavity therapies. This will allow optimization of locally administered therapies 
and aid in the development of agents that target the post-surgical effects on tumor properties. 
CCL5 was identified as a molecule that contributes to the increased proliferation and 
migration after surgical resection. As such, one of the future studies should use a small molecule 
or antibody blocker towards this chemokine. After local or systemic administration of this blocker 
in the GBM resection model, the tumor volumes can be monitored for changes in growth rates. In 
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addition, it would be useful to characterize tumor microenvironment in this situation to examine 
whether administration of the blocker would alter cellular and molecular components. Learning 
how the tumor microenvironment is influenced may help to optimize therapy. If successful, this 
may lead to the integration of this approach with the standard treatment regimen for GBM patients.  
As shown in Chapter 2, the molecular events following surgical resection play a major role 
in tumor progression and invasion.167,186,187,205,206 We found that recurrent tumors are highly 
invasive and exhibited significantly faster growth compared to their non-resected counterparts. In 
this study, we focused on how reactive astrocytes within the peri-tumoral microenvironment 
influences tumor aggressiveness. Using an in vitro model that mimics the in vivo astrocyte 
response to injury,197-200,207 we found the astrocyte response to injury promotes tumor proliferation 
and migration, suggesting that reactive astrocytes may potentiate tumor aggressiveness after 
resection. Since in vitro tumor growth showed marginal increase compared to the in vivo response, 
this suggests reactive astrocytes may only be a contributing factor responsible for promoting the 
increased proliferation of recurrent tumors. Other cell types have been implicated in influencing 
tumor properties such as microglia/macrophages. We discovered these cells to be more abundant 
in the post-surgical cavity (Figure 2.39). Microglia/macrophages cells are likely to play an 
important role in the post-surgical microenvironment and may potentiate the aggressiveness of 
recurrent tumors as they have been implicated in glioma pathogenesis and may promote a tumor-
permissive microenvironment.168,208-212 As such, we can identify the prevalent macrophage 
subtype within and around the post-surgical tumor. Once identified, approaches can be employed 
to either inhibit or convert the macrophage into an alternative subtype. One such method is using 
an ERK or ROS inhibitor to prevent the differentiation of M2 macrophages, cells that have been 
previously implicated in tumor promotion.270 In addition, incorporating other cell types such as 
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macrophages into astrocyte injury model can create a better in vitro system to model the peri-
tumoral microenvironment response after surgical resection. This will allow for creation of a 
model that can be used to predict the aggressiveness of different tumor types and perform high 
through-put in vitro screening of small molecule drug inhibitor.   
Surgical intervention alters the cellular component within the tumor microenvironment and 
may have deleterious consequences on patient survival. While tumor resection is universal for 
aggressive intracranial tumors, this report highlights the role of surgery in inducing a more 
favorable microenvironment for tumor regrowth and recurrence. This suggest that our model may 
provide the means to further understand how the post-surgical microenvironment influences tumor 
properties and allow for the development of drugs to combat resection-mediated effects. By 
concentrating on the astrocyte-mediated component, our data has identified promising secreted 
proteins that may contribute to increased tumor invasion and proliferation after GBM resection. 
Although, these protein candidates were found through RNA profiling with subsequent protein 
validation of the top 5 up-regulated.  This biases the approach to up-regulated candidates at the 
RNA level. Though, an increase in RNA does not necessarily translate to increases in protein 
expression, and vice versa. Thus, a better approach would be to perform protein profiling on brain 
sections. In theory, this would give the truest read of the up-regulated proteins. Matrix-assisted 
laser desorption ionization mass spectrometry (MALDI-MS) is an instrument that can give a 
shotgun method of detecting a broad range of protein signatures on a thin slice of tissue. 
Additionally, this machine can give spatial intensities of each protein, providing a method to 
identify protein candidates in close proximity to the tumor. However, this is a complex approach 
that would be both time consuming to develop the protocols and expensive. 
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Stem cell therapy has been shown to be effective against intracranial tumors, though the 
presence of surgical resection reduces stem cell persistence and in turn, reduces therapeutic 
efficacy.31,66,67 Thus, the findings in Chapter 3 revealed that sECM scaffolds are a promising 
approach for intra-cavity cytotoxic SC therapy of surgically resected GBM. Administering stem 
cells loaded on sECM scaffolds ameliorates the surgery-mediated SC loss, increases the 
therapeutic response, and prolongs survival in tumor-bearing mice. This study provides a solution 
to a clinical problem, in which clinicians would be able deliver cytotoxic SC/sECM scaffolds into 
the resection cavity following GBM removal in human patients. 
It may be useful in future experiments to determine how different scaffold properties such 
as pore size, cross-link density, and degradation rates influence aspects of stem cell therapy. By 
improving SC properties such as SC retention and migration, it would ultimately increase 
therapeutic efficacy. In addition, determining how different materials impact gene expression 
changes within the SCs could also lead to the creation of materials that maintain or improve stem 
cell characteristics. Optimizing the scaffold material and architecture would provide the 
foundation for the ideal scaffold for stem cell therapy.  
Combining stem cell scaffolds with small molecule drugs from chapter 2, will create a local 
combination therapy that will target the post-surgical tumor using multiple pathways. The small 
molecule inhibitor will reduce the surgery-mediated tumor progression and cytotoxic SCs will 
provide long-lasting global tumor killing. Though, there may be some limitations as the drug may 
lower SC viability or have other impacts on these cells. Thus, this approach would require 
extensive testing to determine how the loaded small molecule drugs influence SCs or SC therapy. 
Little is known about the consequences of surgery on MB tumor biology and the impact on local 
therapies. Though, reports have shown that the post-surgical disease is genetically and 
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phenotypically different than the pre-resected tumor suggesting differential treatment responses 
between them.256 In Chapter 4, we developed a novel MB resection model that allowed us to study 
the impact that surgery imparts on MB tumor recurrence and test our stem cell therapies on the 
post-surgical disease. We found that recurrent tumor grew significantly faster than non-resected 
though, our stem cell therapies were effective at regressing post-surgical tumors and significantly 
extended survival in mice. This study suggests that intra-cavity NSC therapy is a viable new option 
to effectively control post-operative tumor growth in MB patients.  
The invasive nature of MB creates enormous drug delivery challenges. This tumor 
frequently invades the ventricles, disseminate into the CSF, travel within the subarachnoid space 
and spread to other regions within the CNS.15,245,247,248,257 Though our stem cell therapy can migrate 
towards cancer cells, ‘suicide’ gene therapy may not allow the stem cells adequate time to travel 
to distant populations. Thus alternative methods are needed that would allow therapeutic stem cells 
more time or opportunity to reach tumor cells that are in distant intracranial locations, or within 
the CSF. We believe intracerebroventricular (ICV) may be such a solution. NSCs administered 
delivered using this method would be immediately in close proximity to cancer cells within the 
CSF and micro-metastatic populations. We are currently exploring and characterizing the efficacy 
of this approach.  
Another component of the standard of care for MB and GMB is radiotherapy (RT). We are 
currently creating a mouse model that involves both RT and resection, increasing the clinical 
relevance of our model. With this model, we can investigate whether SC therapy can improve 
therapeutic efficacy when combined with RT. One apparent limitation of this approach is RT 
killing and reducing the persistence of the therapeutic SCs. These limitations can be minimized by 
using SCs that are not highly proliferative but persist for a long period of time in vivo. This would 
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reduce the killing effects of the RT therapy on SCs and maintain the therapeutic efficacy of the 
cytotoxic SC therapy. If integrating SC therapy with the standard treatment regimen increase 
survival, SC therapy will have an easier path to clinics as it will not be necessary to withhold the 
standard of care from patient for an experimental procedure. Also, a model with both RT and 
resection would provide an ideal, clinically relevant drug development platform in which to test 
preclinical drug candidates. Our data suggests NSC therapy is effective against GBM and MB. 
Though, we incorporated surgical resection in the preclinical models to mimic the clinical scenario, 
other components of the standard treatment regimen needs to be included to fully imitate the 
clinical paradigm. Little is known about how radiotherapy or chemotherapy effects NSC therapy. 
To address this gap, we are exploring how these therapies influence cytotoxic NSCs and how to 
make stem cell therapy synergize with the standard of care.  
In conclusion, our studies demonstrate the development of SC therapies that target post-
surgical tumors and also evaluated and applied these in novel pre-clinical GBM and MB resection 
mouse models. Surgical resection is part of the standard of care for aggressive brain cancers such 
as GBM and MB, which are common in older adults and children, respectively. Since little is 
known about the post-surgical cavity due to a paucity of clinically-relevant pre-clinical models, 
we developed novel GBM and MB resection and recurrence models in order to test our stem cell 
therapies. In chapter 2, we developed the first image-guided mouse GBM resection and recurrence 
model in immune-competent animals. We found that post-resected tumors grows more rapidly 
than their non-resected counterparts and this response was likely promoted by cellular components 
of the peri-tumoral microenvironment undergoing its natural injury response. In chapter 3, we 
loaded SCs on scaffold technologies to determine whether this can improve post-surgical SC 
therapy and provide a better understanding of the ideal scaffold properties for this approach. We 
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found that intra-cavity administration of cytotoxic SCs inhibited post-surgical tumor progression 
and prolonged median survival. We then extended the application of this technology in chapter 4, 
where we used SC loaded scaffolds against MB. Though this new model provided new challenges, 
SC therapy delayed, and in one model, regressed post-surgical tumor progression. Using these 
studies as a foundation, they should allow development and optimization of stem cell therapies 
against intracranial tumors. In addition, these models can be used to provide a better understanding 
of the post-surgical tumor microenvironment and allow for the development of other targeted anti-
cancer agents that improve surgery-mediated effects on tumor biology. 
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